

=> b reg  
 FILE 'REGISTRY' ENTERED AT 18:18:59 ON 03 MAR 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2008 HIGHEST RN 1006303-40-7  
 DICTIONARY FILE UPDATES: 2 MAR 2008 HIGHEST RN 1006303-40-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l9

L5 STR



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE  
 L7 908950 SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES  
 L9 739 SEA FILE=REGISTRY SUB=L7 SSS FUL L5

100.0% PROCESSED 222075 ITERATIONS 739 ANSWERS  
 SEARCH TIME: 00.00.06

=> b hcap  
 FILE 'HCAPLUS' ENTERED AT 18:19:18 ON 03 MAR 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
 held by the publishers listed in the PUBLISHER (PB) field (available  
 for records published or updated in Chemical Abstracts after December  
 26, 1996), unless otherwise indicated in the original publications.  
 The CA Lexicon is the copyrighted intellectual property of the  
 the American Chemical Society and is provided to assist you in searching  
 databases on STN. Any dissemination, distribution, copying, or storing  
 of this information, without the prior written consent of CAS, is  
 strictly prohibited.

FILE COVERS 1907 - 3 Mar 2008 VOL 148 ISS 10  
FILE LAST UPDATED: 2 Mar 2008 (20080302/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d bib abs hitrn fhitr 112 tot

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on SIN  
 AN 2005:76240 HCAPLUS  
 DN 142:176839  
 TI Preparation of heterocycloalkylmethylimidazoles and related compounds as  
 C5a receptor modulators for the treatment of inflammatory disorders  
 IN Zhang, Suoming; He, Zhao; Gao, Yang; Thurkauf, Andrew; Maynard, George;  
 Bertrand, Chénard; Ohliger, Robert; Peterson, John M.  
 PA Neurogen Corporation, USA  
 SO PCT Int. Appl., 137 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 PAN\_CNT 1

| PATENT NO.                                                                                                                                                                                                                                                                                                                                                                                        | KIND | DATE     | APPLICATION NO.  | DATE     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|----------|
| PI WO--2005007087                                                                                                                                                                                                                                                                                                                                                                                 | A2   | 20050127 | 2004WO-US0021191 | 20040630 |
| WO--2005007087                                                                                                                                                                                                                                                                                                                                                                                    | A3   | 20060330 |                  |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DS, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SF, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                  |          |
| RW: BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SE, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG                                                                                                                    |      |          |                  |          |
| US--2006154917                                                                                                                                                                                                                                                                                                                                                                                    | A1   | 20060713 | 2006US-000563401 | 20060103 |
| PRAI 2003US-00484684P                                                                                                                                                                                                                                                                                                                                                                             | P    | 20030703 |                  |          |
| 2004WO-US0021191                                                                                                                                                                                                                                                                                                                                                                                  | W    | 20040630 |                  |          |
| OS MARPAT 142:176839                                                                                                                                                                                                                                                                                                                                                                              |      |          |                  |          |
| GI                                                                                                                                                                                                                                                                                                                                                                                                |      |          |                  |          |

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [A = O, S, NR; X = J; Y = K; Z = (L)m; Q = Ar1; n = 0-2; J, K, L = O, S, NR, etc. with provisos; R = alkyl, alkenyl, alkynyl, etc.; R1 = H, OH, halo, etc.; R2, R3 = H, alkyl; R4 = alkyl, alkenyl, alkynyl, etc.; R5 = OH, halo, amino, etc. with provisos; Ar1 = (unsubstituted Ph, naphthyl, heteroaryl, etc.) and their pharmaceutically acceptable salts and formulations were prepared For example, N-alkylation of 2-benzo[1,3]dioxol-5-ylpiperidine with chloride II, e.g., prepared from 4,5-dichloromimidazole in 6-steps, afforded methylimidazole III. Compds. I are claimed to be modulators of C5a receptors, preferably bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors.

IT 832153-16-9P 832153-17-0P 832153-18-1P  
 832153-19-2P 832153-20-5P 832153-21-6P  
 832153-22-7P 832153-23-8P 832153-24-9P  
 832153-25-0P 832153-26-1P 832153-27-2P  
 832153-28-3P 832153-29-4P 832153-30-7P  
 832153-31-8P 832153-32-9P 832153-33-0P  
 832153-34-1P 832153-35-2P 832153-36-3P  
 832153-37-4P 832153-38-5P 832153-39-6P  
 832153-40-9P 832153-41-0P 832153-42-1P  
 832153-43-2P 832153-44-3P 832153-45-4P  
 832153-46-5P 832153-47-6P 832153-48-7P  
 832153-49-8P 832153-50-1P 832153-51-2P  
 832153-52-3P 832153-53-4P 832153-54-5P  
 832153-55-6P 832153-56-7P 832153-57-8P  
 832153-58-9P 832153-59-0P 832153-60-3P  
 832153-61-4P 832153-62-5P 832153-63-6P  
 832153-64-7P 832153-65-8P 832153-66-9P  
 832153-67-0P 832153-68-1P 832153-69-2P  
 832153-70-5P 832153-71-6P 832153-72-7P  
 832153-73-8P 832153-74-9P 832153-75-0P  
 832153-76-1P 832153-77-2P 832153-78-3P

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

832153-79-4P 832153-80-7P 832153-81-8P  
 832153-82-9P 832153-83-0P 832153-84-1P  
 832153-85-2P 832153-86-3P 832153-87-4P  
 832153-88-5P 832153-89-6P 832153-90-9P  
 832153-91-0P 832153-92-1P 832153-93-2P  
 832153-94-3P 832153-95-4P 832153-96-5P  
 832153-97-6P 832153-98-7P 832153-99-8P  
 832154-00-4P 832154-01-5P 832154-02-6P  
 832154-03-7P 832154-04-8P 832154-05-9P  
 832154-06-0P 832154-07-1P 832154-08-2P  
 832154-09-3P 832154-10-6P 832154-11-7P  
 832154-12-8P 832154-13-9P 832154-14-0P  
 832154-15-1P 832154-16-4P 832154-17-5P  
 832154-18-6P 832154-19-7P 832154-20-8P  
 832154-21-9P 832154-22-0P 832154-23-1P  
 832154-24-2P 832154-25-3P 832154-26-4P  
 832154-27-5P 832154-28-6P 832154-29-7P  
 832154-30-8P 832154-31-9P 832154-32-0P  
 832154-33-1P 832154-34-2P 832154-35-3P  
 832154-36-4P 832154-37-5P 832154-38-6P  
 832154-39-7P 832154-40-8P 832154-41-9P  
 832154-42-0P 832154-43-1P 832154-44-2P  
 832154-45-3P 832154-46-4P 832154-47-5P  
 832154-48-6P 832154-49-7P 832154-50-8P  
 832154-51-9P 832154-52-0P 832154-53-1P  
 832154-54-2P 832154-55-3P 832154-56-4P  
 832154-57-5P 832154-58-6P 832154-59-7P  
 832154-60-8P 832154-61-9P 832154-62-0P  
 832154-63-1P 832154-64-2P 832154-65-3P  
 832154-66-4P 832154-67-5P 832154-68-6P  
 832154-69-7P 832154-70-8P 832154-71-9P  
 832154-72-0P 832154-73-1P 832154-74-2P  
 832154-75-3P 832154-76-4P 832154-77-5P  
 832154-78-6P 832154-79-7P 832154-80-8P  
 832154-81-9P 832154-82-0P 832154-83-1P  
 832154-84-2P 832154-85-3P 832154-86-4P  
 832154-87-5P 832154-88-6P 832154-89-7P  
 832154-90-8P 832154-91-9P 832154-92-0P  
 832154-93-1P 832154-94-2P 832154-95-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of heterocycloalkylmethylimidazoles and related compds. as C5a receptor modulators for the treatment of inflammatory disorders)  
 IT 832153-05-2P 832153-06-3P 832153-07-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of heterocycloalkylmethylimidazoles and related compds. as C5a receptor modulators for the treatment of inflammatory disorders)  
 IT 832153-16-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocycloalkylmethylimidazoles and related compds. as C5a receptor modulators for the treatment of inflammatory disorders)  
 RN 832153-16-9 HCAPLUS  
 CN Piperidine, 1-[(1-butyl-4-chloro-2-(2,6-diethylphenyl)-1H-imidazol-5-yl)methyl]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



=> d bib abs hitstr 128 tot

L28 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN  
 AN 1957:2050 HCAPLUS  
 DN 51:2050  
 OREF 51:487d-g  
 TI Diphenyldihydro- and -tetrahydroglyoxalin-4-one  
 IN Goodman, Louis S.  
 DT Patent  
 LA Unavailable  
 FAN.CNT 1

| PATENT NO.     | KIND  | DATE     | APPLICATION NO.  | DATE     |
|----------------|-------|----------|------------------|----------|
| US-----2744852 | ----- | 19560508 | 1953US-000387519 | 19531021 |

PI For diagram(s), see printed CA Issue.  
 GI NH<sub>2</sub>CH<sub>2</sub>NH.CO.CPh<sub>2</sub> (I) and N:CH.NH.CH.CPh<sub>2</sub> (II) were prepared as  
 AB anticonvulsants. A solution of 12.5 g. benzil and 10 g. H<sub>2</sub>NCSNH<sub>2</sub> in 250 cc.  
 EtOH containing 3 g. KOH refluxed 3 hrs., the mixture diluted with 1500 cc. water,  
 a small amount of precipitate filtered off, and the filtrate acidified by addition of  
 2N HCl gave 17 g. NH.CS.NH.CO.CPh<sub>2</sub> (III) which on crystallization from EtOH formed  
 almost colorless needles, m. 234°. III (5 g.) in 125 cc. EtOH  
 containing 25 g. Raney Ni catalyst refluxed 5 hrs., the warm mixture filtered,  
 the filtrate concentrated to approx. 25 cc., and a few drops of water added gave  
 3 g. I, colorless plates, m. 183° (from MeOH). I (10 g.) in 300  
 cc. warm 0.7N HCl added slowly with stirring to 400 cc. 2N NaOH, the mixture  
 diluted with 600 cc. water, warmed to 55°, a solution of 4 g. KMnO<sub>4</sub> in  
 200 cc. warm water added dropwise over 10 min., the mixture stirred an  
 addnl. 5 min., filtered, 100 g. NaOAc in 400 cc. water added to the  
 filtrate, the mixture cooled to 0°, the pH adjusted to 6.0-6.5 with  
 dilute HCl, and the product filtered off and crystallized from EtOAc gave II,  
 white, m. 167.5-8.5°. Utilizable pharmaceutical preps. of I and  
 II are described.

L28 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN  
 AN 1957:2049 HCAPLUS  
 DN 51:2049  
 OREF 51:486i,487a-d  
 TI 4-(β-Substituted aminoethyl)imidazoles  
 IN Huebner, Charles F.  
 PA Ciba Pharmaceutical Products, Inc.  
 DT Patent  
 LA Unavailable  
 FAN.CNT 1

| PATENT NO.     | KIND  | DATE     | APPLICATION NO.  | DATE     |
|----------------|-------|----------|------------------|----------|
| US-----2744899 | ----- | 19560508 | 1951US-000213668 | 19510302 |

PI For diagram(s), see printed CA Issue.  
 GI Imidazole compds. characterized by histaminelike activity are prepared by  
 AB treating HOCH<sub>2</sub>COCH:CH<sub>2</sub> (I) with a secondary amine to form the  
 corresponding β-aminoethyl hydroxymethyl ketone which is then treated  
 with an aldehyde and concentrated aqueous NH<sub>3</sub> in the presence of Cu<sup>++</sup> to form the  
 imidazole N:CR.NH.CH(CCH<sub>2</sub>CH<sub>2</sub>R') (II), where R is H, alkyl, or aryl and R'  
 is a dialkylamino radical or a cycloaliphatic amino group like piperidino  
 or morpholino. To 6% aqueous I 100 parts (by volume) is added piperidine 6 (by  
 volume), after standing 15 min. at room temperature the solution added to a solution of  
 Cu(OAc)<sub>2</sub> 20 and 36% aqueous CH<sub>2</sub>O 15 (by volume) in concentrated aqueous NH<sub>3</sub> 225 (by volume),  
 the mixture heated 1 hr. on the steam bath, the precipitate collected, suspended in  
 hot water 100 (by volume), H<sub>2</sub>S passed through the mixture while adding concentrated  
 HCl slowly to maintain the mixture acid to Congo red, decolorizing C added,  
 the precipitated CuS filtered off, the filtrate concentrated to dryness, and the  
 residue crystallized from EtOH-MeCOEt gave II.2HCl (R = H, R' = piperidino)  
 (III), m. 275-8°. III 20 warmed with Na<sub>2</sub>CO<sub>3</sub> 20 and water 20 (by  
 volume), the oil extracted several times with EtOAc, the extract dried, the EtOAc  
 removed in vacuo, and the residual oil distilled gave the free base, b10  
 200-10°, crystallizing on standing and m. 104-6°. Similarly, the  
 following II (R, R', and m.p. of indicated salts given): H, Me<sub>2</sub>N, picrate  
 229-30° (from water), di-HCl 184-5° (from MeCOEt); H, Et<sub>2</sub>N,  
 di-HCl 217-20°; H, Pr<sub>2</sub>N, dipicrate 190°; Me, piperidino,  
 dipicrate 153-4°, di-HCl sirup; Et, piperidino, dipicrylsulfonate  
 253° (from water), di-HCl sirup; Ph, piperidino, (base)  
 156-8° (from EtOH-water); Ph, Me<sub>2</sub>N, dipicrate 218-20°,  
 di-HCl 270-5°; H, morpholino, di-HCl 238-43° (from  
 EtOH-Et<sub>2</sub>O).


=> d bib abs hitstr l24 tot

L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN  
 RN 2003:5808 HCAPLUS  
 DN 138:106702

TI Preparation of 4-aminomethyl-2-substituted imidazole derivatives and  
 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine  
 receptor subtype specific ligands  
 IN Thurkauf, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.  
 PA Neuron Corporation, USA  
 SO U.S. Pat. Appl. Publ., 37 pp., Cont. of U.S. Ser. No. 281,169.  
 CODEN: USXXCO

DT Patent  
 LA English  
 FAN.CNT 1

| PATENT NO.            | KIND | DATE     | APPLICATION NO.  | DATE         |
|-----------------------|------|----------|------------------|--------------|
| PI US--2003018025     | A1   | 20030123 | 2002US-000156262 | 20020528 <-- |
| PRAI 1995US-000478291 | B1   | 19950607 | <--              |              |
| 1999US-000281169      | A1   | 19990330 | <--              |              |
| GI MARPAT 138:106702  |      |          |                  |              |



AB The imidazoles I (R1 = optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl, naphthyl; X, Z, and Y = optionally substituted nitrogen or carbon atoms; R2 = H, alkyl; n = 0, 1 or 2; and R3 and R4 = H, alkyl, R3R4N may form a ring) and the pharmaceutically acceptable addition salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Thus, 2-phenyl-4-(hydroxymethyl)imidazole was treated with SOCl2 followed by 1-(2-methoxyphenyl)piperazine to give 2-phenyl-4(5)-[4-(2-methoxyphenyl)piperazin-1-yl)methyl]imidazole.


2-Phenyl-4(5)-[4-(2-pyrimidinyl)piperazin-1-yl)methyl]imidazole dihydrochloride was shown to bind to the dopamine D4 receptor site (K1 = 1033, 8200, 2.7 for D2, D3, D4 binding sites, resp.).  
 IT 144649-79-6P 144649-80-9P 144649-81-0P  
 144649-82-1P 144649-98-9P 178928-64-6P  
 178928-66-0P 179332-10-6P 179332-11-7P  
 179332-13-9P 179332-14-0P 179332-15-1P  
 179332-16-2P 179332-17-3P 179332-18-4P  
 179332-19-5P 179332-27-5P 179332-28-6P  
 179332-29-7P 179332-30-0P 179332-31-1P  
 179332-32-2P 179332-35-5P 179332-36-6P  
 179332-44-6P 179332-63-9P 179332-64-0P  
 179332-68-4P 179332-78-6P 179332-81-1P  
 179332-92-4P 179332-98-0P 179333-00-7P  
 179333-17-6P 179333-38-1P 179333-39-2P  
 179333-40-5P 179333-41-6P 179333-42-7P  
 179333-43-8P 179333-49-4P 179333-50-7P  
 179333-62-1P 179333-69-8P

RL: PAC (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BIOB (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole derivs. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)


RN 144649-79-6 HCAPLUS  
 CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● 2 HCl

RN 178928-64-8 HCAPLUS  
 CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 178928-66-0 HCAPLUS  
 CN Pyridine, 2-[1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 179332-10-6 HCAPLUS  
 CN Piperidine, 1-[(2-(4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 179332-11-7 HCAPLUS  
 CN Piperidine, 1-[(2-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● 2 HCl

RN 144649-80-9 HCAPLUS  
 CN Piperidine, 4-phenyl-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 144649-81-0 HCAPLUS  
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 144649-82-1 HCAPLUS  
 CN Isoquinoline, 2-[(2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 144649-98-9 HCAPLUS  
 CN Piperidine, 1-[(2-(5-chloro-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● 2 HCl

RN 179332-13-9 HCAPLUS  
 CN Piperidine, 1-[(2-(2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179332-14-0 HCAPLUS  
 CN Piperidine, 1-[(2-(3-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179332-15-1 HCAPLUS  
 CN Piperidine, 1-[(2-(3-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




RN 179332-16-2 HCAPLUS  
 CN Piperidine, 1-[(2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



RN 179332-17-3 HCAPLUS  
 CN Piperidine, 1-[(2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, (2S)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 1  
CRN 179332-16-2  
CMF C21 H22 F N3




CM 2  
CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 179332-18-4 HCAPLUS  
CN Piperidine, 1-[(2-(2-methylphenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179332-19-5 HCAPLUS  
CN Piperidine, 1-[(2-(5-ethyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179332-27-5 HCAPLUS  
CN Piperidine, 1-[(2-(4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 179332-31-1 HCAPLUS  
CN Piperidine, 1-[(2-(4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179332-32-2 HCAPLUS  
CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 179332-35-5 HCAPLUS  
CN Piperidine, 1-[(2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 179332-36-6 HCAPLUS  
CN Piperidine, 1-[(2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, (2S)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 179332-35-5  
CMF C22 H24 F N3




L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 179332-28-6 HCAPLUS  
CN Piperidine, 4-(4-fluorophenyl)-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, (2S)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 179332-27-5  
CMF C21 H22 F N3




CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 179332-29-7 HCAPLUS  
CN Piperidine, 1-[(2-(3-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 179332-30-0 HCAPLUS  
CN Piperidine, 1-[(2-(3-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, (2S)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 179332-29-7  
CMF C22 H24 F N3



CM 2

L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CM 2

CRN 110-16-7  
CMF C4 H4 O4


Double bond geometry as shown.



RN 179332-44-6 HCAPLUS  
CN Piperidine, 1-[(1-methyl-2-phenyl-1H-imidazol-5-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 179332-43-9 HCAPLUS  
CN Piperidine, 1-[(1-(2-phenyl-1H-imidazol-4-yl)ethyl)-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179332-64-0 HCAPLUS  
CN Piperidine, 1-[(2-(1-naphthalenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 179332-68-4 HCAPLUS  
CN Piperidine, 1-[(2-(2-naphthalenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 179332-78-6 HCAPLUS  
CN Pyrazine, 1-[(4-(phenylmethyl)-1-piperidinyl)methyl]-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 179332-81-1 HCAPLUS  
CN Piperidine, 4-(phenylmethyl)-1-[(2-(2-thienyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 179332-92-4 HCAPLUS  
CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[(1-oxo-3-(2-phenyl-1H-imidazol-4-yl)propyl)-2-propenyl]- (9CI) (CA INDEX NAME)



RN 179332-98-0 HCAPLUS  
CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[(3-(2-phenyl-1H-imidazol-4-yl)propyl)-2-propenyl]- (9CI) (CA INDEX NAME)




RN 179333-00-7 HCAPLUS  
CN Piperidine, 1-[(2-(2-cyclohexyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 179333-17-6 HCAPLUS  
CN Piperidine, 1-[(2-(2-phenyl-1H-imidazol-4-yl)carbonyl)-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 179333-38-1 HCAPLUS  
CN Piperidine, 1-[(2-(4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 179333-39-2 HCAPLUS  
CN Piperidine, 1-[(2-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 179333-40-5 HCAPLUS  
CN Piperidine, 1-[(2-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 179333-41-6 HCAPLUS  
CN Piperidine, 1-[(2-(3-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 179333-42-7 HCAPLUS  
CN Piperidine, 1-[(2-(2-methylphenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 179333-43-8 HCAPLUS  
CN Piperidine, 1-[(2-(5-ethyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 179333-49-4 HCAPLUS  
CN Piperidine, 1-[(2-(4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 179333-50-7 HCAPLUS  
CN Piperidine, 4-[(4-fluorophenyl)methyl]-1-[(2-phenyl-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 179333-62-1 HCAPLUS  
CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 179333-69-8 HCAPLUS  
CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L24 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:927246 HCAPLUS

IN 138:8349

TI Combination of a dopamine D2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases

IN Yeadon, Michael

PA Boehringer Ingelheim Pharma KG, Germany

SO PCT Int. Appl., 122 pp.

COSEN: P1XXD2

DT Patent

LA English

FAM,CHI 1

| PATENT NO.                                                                                                                                                                                                                                                                                                                                                                | KIND | DATE     | APPLICATION NO.  | DATE         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|--------------|
| WO--2002096422                                                                                                                                                                                                                                                                                                                                                            | A2   | 20021205 | 2002WO-EP0005642 | 20020523 <-- |
| WO--2002096422                                                                                                                                                                                                                                                                                                                                                            | A3   | 20030320 |                  |              |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LD, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NI, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW |      |          |                  |              |
| RW: GH, GM, KE, LS, MW, ME, SD, SL, SS, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG                                                                                                                                                                        |      |          |                  |              |
| CA-----2445650                                                                                                                                                                                                                                                                                                                                                            | A1   | 20021205 | 2002CA-002445650 | 20020523 <-- |
| AU--2002314101                                                                                                                                                                                                                                                                                                                                                            | A1   | 20021109 | 2002AU-002314101 | 20020523 <-- |
| EP-----1397134                                                                                                                                                                                                                                                                                                                                                            | A2   | 20040317 | 2002EP-000740637 | 20020523 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, SL, LV, FI, RO, MK, CY, AL, TR                                                                                                                                                                                                                                                                 |      |          |                  |              |
| JP--2004538267                                                                                                                                                                                                                                                                                                                                                            | T    | 20041224 | 2002JP-000592932 | 20020523 <-- |
| US--2007117788                                                                                                                                                                                                                                                                                                                                                            | A1   | 20070524 | 2003US-000720050 | 20031119 <-- |
| MX--200309A10797                                                                                                                                                                                                                                                                                                                                                          | A    | 20040302 | 2003MX-PA0010797 | 20031125 <-- |
| PRAI 2001US-00293630P                                                                                                                                                                                                                                                                                                                                                     | P    | 20010525 | <--              |              |
| 2001US-00303859P                                                                                                                                                                                                                                                                                                                                                          | P    | 20010709 | <--              |              |
| 2002WO-EP0005642                                                                                                                                                                                                                                                                                                                                                          | W    | 20020523 | <--              |              |

OS

MAPAT 138:8349



AB She present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (i) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (ii) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivs. thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmacologically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.

IT



477281-26-8 477281-27-9  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination of dopamine D2-receptor agonist and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases)

RN 477281-26-8 HCAPLUS

CN Piperidine, 4-phenyl-1-[(2-phenyl-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



| PATENT NO.                                                                                                                                                                                                                                                                                                                 | KIND | DATE         | APPLICATION NO.  | DATE          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|--------------|------------------|---------------|
| PI WO--200729186                                                                                                                                                                                                                                                                                                           | A2   | 20021010     | 2020MO-EP0003193 | 20200321 <--  |
| WO--200729186                                                                                                                                                                                                                                                                                                              | A2   | 20021010     |                  |               |
| WE, AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, DE, DK, DM, EE, EC, ES, FI, FR, GB, GD, GE, GH, GR, HK, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LA, MG, MN, MW, MX, MY, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW |      |              |                  |               |
| RM: GM, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, JP, MC, MG, MN, MW, MY, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW                             |      |              |                  |               |
| CA--2441178                                                                                                                                                                                                                                                                                                                | A    | 20021010     | 2002CA-002441178 | 20200321 <--  |
| AE--2004773                                                                                                                                                                                                                                                                                                                | A    | 20021015     | 2002AE-0004773   | 20200321 <--  |
| FR--200208572                                                                                                                                                                                                                                                                                                              | A    | 20040030     | 2002FR-00008572  | 20200321 <--  |
| EP--20041720                                                                                                                                                                                                                                                                                                               | A2   | 20040512     | 2002EP-000732512 | 20200321 <--  |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, SI, ES, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW                                                                                                                                                                                          |      |              |                  |               |
| CN--2500086                                                                                                                                                                                                                                                                                                                | A    | 20040526     | 2002CN-000807803 | 20200321 <--  |
| JP--24528318                                                                                                                                                                                                                                                                                                               | A    | 20040916     | 2002JP-000577812 | 20200321 <--  |
| US--2004092760                                                                                                                                                                                                                                                                                                             | A    | 20040910     | 2002US-00092760  | 20200321 <--  |
| ZA--200306690                                                                                                                                                                                                                                                                                                              | A    | 20041203     | 2003ZA-00006690  | 202003903 <-- |
| MX--2003P08093                                                                                                                                                                                                                                                                                                             | A    | 20050307     | 2003MX-P0006931  | 202003903 <-- |
| PR:AE--200008099                                                                                                                                                                                                                                                                                                           | A    | 20010330     |                  |               |
| 2020MO-EP0003193                                                                                                                                                                                                                                                                                                           | W    | 20200321 <-- |                  |               |
| OS MARPAT 13729193                                                                                                                                                                                                                                                                                                         |      | 20200321 <-- |                  |               |



L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

pharmacofenancers.

4-Benzyl-3-methyl-1-[1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-25-6P 46663-30-9P

1-Benzyl-1-[1-(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-32-1P

1-Benzyl-1-[1-(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-33-1P

1-Benzyl-1-[1-(5-methyl-2-phenyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-34-1P

1-Benzyl-1-[1-(5-methyl-2-phenyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-35-5P, 1-(4-Methoxyphenyl)-3-methyl-1-[1-(2-(2,3-dimethoxyphenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-56-9P, 3-Methyl-1-phenyl-1-[1-[(2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-58-1P, 1-[1-[(2-(3,5-Dimethoxyphenyl)-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-60-2P, 1-[1-[(2-(3,5-Dimethoxyphenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]-3-methyl-1-phenylurea 46663-60-5P,

1-Benzyl-1-[1-(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-62-2P

1-Allyl-1-[1-(5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-63-6P

1-Benzyl-3-methyl-1-[2-(5-methyl-2-p-tolyl-1H-imidazo-4-yl)methyl]piperidin-6-ylurea 46663-65-6P, 1-Benzyl-1-[1-[(1-(2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl)piperidin-4-yl]-3-methylurea 46663-66-1P, 1-Benzyl-1-[1-(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl]piperidin-4-yl]-3-pyridin-2-ylurea 46663-67-3P, 46664-25-5P, 3-(5-Dibenzyl-1-[1-(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl]-4-piperidinyl]urea 46663-66-26-6P, 1-[1-[(2-(4-(trifluoromethyl)phenyl)-1H-imidazo-4-yl)methyl]-4-piperidinyl]-3-methylurea 46663-25-8P, 1-Cyclohexyl-1-[1-[(2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]-3-methylurea 46664-30-2P, 1-[1-[(2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]-3-methyl-1-(2-pyridinyl)urea 46664-32-4P

Trifluoromethyl-phenyl-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl-3-methyl-1-(3-phenylpropyl)urea 46664-34-6P

1-[1-[(2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]-1-pyridinyl]urea 46664-35-2P

1-(4-Chlorobenzyl)-1-[1-[(2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]-3-methylurea 46664-36-8P,

1-(4-Chlorobenzyl)-1-[1-[(2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]-3-methyl-1-(4-pyridyl)methylurea 46664-37-8P

1-Benzyl-3-methyl-1-[1-[(2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]-3-propylurea 46664-39-1P


1-Benzyl-1-[1-[(2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazo-4-yl)methyl]-4-piperidinyl]-3-phenylurea 46664-40-4P,

L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

[illegible]



L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)  
 1-Benzyl-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-3-(2-methylphenyl)urea 466665-17-9P,  
 1-Benzyl-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-3-(3-methylphenyl)urea 466665-19-0P,  
 1-Benzyl-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-3-(4-methylphenyl)urea 466665-21-4P,  
 1-Benzyl-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-3-(3,5-dimethylphenyl)urea 466665-22-5P,  
 1-Benzyl-3-(2-chlorophenyl)-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinylurea 466665-23-6P,  
 1-Benzyl-3-(3-chlorophenyl)-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinylurea 466665-24-7P,  
 1-Benzyl-3-(3,5-dichlorophenyl)-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinylurea 466665-25-8P,  
 1-Benzyl-3-(4-fluorophenyl)-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinylurea 466665-26-9P,  
 1-Benzyl-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-3-(4-(dimethylamino)phenyl)urea 466665-27-0P, 1-Benzyl-3-(4-cyanophenyl)-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]urea 466665-28-1P, 1-Benzyl-3-(3-bromophenyl)-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]urea 466665-29-2P, 1-Benzyl-3-[3-(trifluoromethyl)phenyl]-1-[1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]urea 466665-30-5P, 1-[1-[[2-(2-Methoxyphenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-3-methyl-1-phenylurea 466665-31-6P, Methyl 5-[[4-[[1-benzyl-3-methylurea]piperidin-1-yl]-2-[[4-(trifluoromethyl)phenyl]-3H-imidazole-4-carboxylate 466665-32-7P, 1-Methyl-3-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-33-8P, 1-Ethyl-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-34-9P, 1-Allyl-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-35-0P, 1-tert-Butyl-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-36-1P, 1-Cyclobutylmethyl-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-37-2P, 1-(2-Methoxyphenyl)-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-38-3P, 1-(4-Methoxyphenyl)-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-39-4P, 1-(2-Chlorophenyl)-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-40-5P, 1-(4-Chlorophenyl)-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-41-6P, 3-Methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-42-7P, 1-(2-Trifluoromethylphenyl)-3-methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-43-8P, 3-Methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-44-9P, 3-Methyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-45-0P, 1-Benzyl-3,3-diethyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-46-1P, 1-Benzyl-1-[1-[[2-(4-tert-butylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-methylurea 466665-48-3P, 3-(4-Aminophenyl)-1-benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-50-5P, 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-pyridin-4-ylurea 466665-51-0P, 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-pyridin-3-ylurea 466665-52-1P, 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-pyridazin-3-ylurea 466665-53-2P, 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-pyridazin-4-ylurea 466665-54-3P,

L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)






L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)  
 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-thiophen-2-ylurea 466665-55-4P,  
 1-Benzyl-3-furan-2-yl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-56-5P,  
 1-Benzyl-3-(5-methyl-1,3,4-thiadiazol-2-yl)-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-57-6P, 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-pyridin-4-ylmethylurea 466665-58-7P, 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-pyridin-3-ylmethylurea 466665-59-8P, 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-pyridin-2-ylmethylurea 466665-60-9P, 1-Benzyl-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-(tetrahydropyran-4-yl)urea 466665-61-0P, 1-Benzyl-2-[1-formylpiperidin-4-yl]-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]urea 466665-62-3P, 1-(4-Aminobenzyl)-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-phenylurea 466665-63-4P, 1-((Biphenyl-2-yl)methyl)-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-phenylurea 466671-73-8P, 1-((Biphenyl-3-yl)methyl)-1-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]-3-phenylurea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (HIV inhibitor; prepn. of imidazolylalkyl-aminopiperidines as HIV inhibitors)


RN 466663-28-5 HCAPLUS  
 CN Urea, N'-methyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)  
 RN 466663-49-0 HCAPLUS  
 CN Urea, N'-methyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-phenyl- (9CI) (CA INDEX NAME)




L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 466663-56-9 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[2-(4-chlorophenyl)-5-methyl-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N'-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 466663-57-0 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N'-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 466663-58-1 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N'-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 466663-59-2 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N'-methyl-N-phenyl- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 466663-66-1 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 466664-23-3 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 466664-25-5 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 466664-26-6 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 466664-27-7 HCAPLUS  
CN Urea, N-butyl-N'-methyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




RN 466663-60-5 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-phenyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 466663-62-7 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-phenyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 466663-64-9 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 466663-65-0 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)

L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 466664-28-8 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 466664-30-2 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 466664-32-4 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 466664-34-6 HCAPLUS  
CN Urea, N'-methyl-N-phenyl-N-[1-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-2-pyridinyl- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-35-7 HCAPLUS  
CN Urea, N-((4-chlorophenyl)methyl)-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 466664-36-8 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-37-9 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-38-0 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(phenylmethyl)-N'-propyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-43-7 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N'-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 466664-44-8 HCAPLUS  
CN Urea, N-(cyclopropylmethyl)-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 466664-45-9 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(phenylmethyl)-N'-propyl)- (9CI) (CA INDEX NAME)




RN 466664-46-0 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(phenylmethyl)-N'-propyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-39-1 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N'-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 466664-40-4 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-41-5 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-42-6 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-47-1 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-([4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 466664-48-2 HCAPLUS  
CN Urea, N-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-49-3 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466664-50-6 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N'-phenyl- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-51-7 HCAPLUS  
CN Urea, N-((2-methoxyphenyl)methyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 466664-52-8 HCAPLUS  
CN Urea, N-((2-methylphenyl)methyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466664-53-9 HCAPLUS  
CN Urea, N-((3,5-dichlorophenyl)methyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466664-54-0 HCAPLUS  
CN Urea, N-((3,4-dichlorophenyl)methyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)

L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN Urea, N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-((4-nitrophenyl)methyl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466664-59-5 HCAPLUS  
CN Urea, N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl-3-[[4-((phenylamino)carbonyl)amino]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 466664-60-8 HCAPLUS  
CN Benzoic acid, 4-[[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]((phenylamino)carbonyl)amino)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 466664-61-9 HCAPLUS  
CN Urea, N-[[4-(methylsulfonyl)phenyl)methyl]-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466664-62-0 HCAPLUS  
CN Urea, N-([1,1'-biphenyl]-4-ylmethyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)

L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


(9CI) (CA INDEX NAME)




RN 466664-55-1 HCAPLUS  
CN Urea, N-((3-methylphenyl)methyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 466664-56-2 HCAPLUS  
CN Urea, N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-((3-nitrophenyl)methyl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466664-57-3 HCAPLUS  
CN Urea, N-[[4-(dimethylamino)phenyl)methyl]-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466664-58-4 HCAPLUS

L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


(9CI) (CA INDEX NAME)




RN 466664-63-1 HCAPLUS  
CN Urea, N-((4-cyanophenyl)methyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 466664-64-2 HCAPLUS  
CN Urea, N'-((4-iodophenyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-65-3 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 466664-66-4 HCAPLUS  
CN Urea, N'-methyl-N-(1-methylethyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-67-5 HCAPLUS  
CN Urea, N'-methyl-N-(2-methylpropyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 466664-68-6 HCAPLUS  
CN Urea, N-cyclopropyl-N'-methyl-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 466664-69-7 HCAPLUS  
CN Urea, N'-(3,4-dichlorophenyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-70-0 HCAPLUS  
CN Benzoic acid, 4-([1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl](phenylmethyl)amino)carbonylamino-, methyl ester (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-97-1 HCAPLUS  
CN Thiourea, N'-methyl-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 466665-01-0 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-((4-phenoxyphenyl)methyl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466665-09-8 HCAPLUS  
CN Urea, N-methyl-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-11-2 HCAPLUS  
CN Urea, N-(cyclopentylmethyl)-N'-methyl-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-71-1 HCAPLUS  
CN Urea, N-(4-chlorophenyl)-N-methyl-N'-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 466664-72-2 HCAPLUS  
CN Urea, N-methyl-N'-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N,N'-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-73-3 HCAPLUS  
CN Urea, N'-cyclopropyl-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466664-74-4 HCAPLUS  
CN Urea, N-([1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)-N'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466665-12-3 HCAPLUS  
CN Benzoic acid, 4-([1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl](phenylmethyl)amino)carbonylamino-, methyl ester (9CI) (CA INDEX NAME)



RN 466665-13-4 HCAPLUS  
CN Urea, N-((4-methylphenyl)methyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466665-14-5 HCAPLUS  
CN Urea, N-((2,4-dimethylphenyl)methyl)-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466665-15-6 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-((2,4,6-trimethoxyphenyl)methyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466665-17-8 HCAPLUS  
CN Urea, N'-(2-methylphenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 466665-18-9 HCAPLUS  
CN Urea, N'-(3-methylphenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-19-0 HCAPLUS  
CN Urea, N'-(4-methylphenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-21-4 HCAPLUS  
CN Urea, N'-(3,5-dimethylphenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466665-26-9 HCAPLUS  
CN Urea, N'-(4-cyanophenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-27-0 HCAPLUS  
CN Urea, N'-(3-bromophenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 466665-28-1 HCAPLUS  
CN Urea, N'-(2-bromophenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-29-2 HCAPLUS  
CN Urea, N'-(2-methoxyphenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-30-5 HCAPLUS  
CN Urea, N'-(2-methoxyphenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-methyl-N-phenyl- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466665-22-5 HCAPLUS  
CN Urea, N'-(2-chlorophenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 466665-23-6 HCAPLUS  
CN Urea, N'-(3-chlorophenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-24-7 HCAPLUS  
CN Urea, N'-(3,5-dichlorophenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-25-8 HCAPLUS  
CN Urea, N'-(4-fluorophenyl)-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466665-31-6 HCAPLUS  
CN 1H-imidazole-4-carboxylic acid, 5-([4-(methyl((phenylmethyl)amino)carbonyl)amino]-1-piperidinyl)methyl)-2-(4-(trifluoromethyl)phenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 466665-32-7 HCAPLUS  
CN Urea, N'-methyl-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-33-8 HCAPLUS  
CN Urea, N'-methyl-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 466665-34-9 HCAPLUS  
CN Urea, N'-methyl-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]-N-2-propenyl- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466665-35-0 HCAPLUS  
CN Urea, N-(1,1-dimethylethyl)-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]- (9CI)  
(CA INDEX NAME)




RN 466665-36-1 HCAPLUS  
CN Urea, N-(cyclobutylmethyl)-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]- (9CI)  
(CA INDEX NAME)




RN 466665-37-2 HCAPLUS  
CN Urea, N-(2-methoxyphenyl)-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]- (9CI)  
(CA INDEX NAME)




RN 466665-38-3 HCAPLUS  
CN Urea, N-(4-methoxyphenyl)-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]- (9CI)  
(CA INDEX NAME)

L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
INDEX NAME)


RN 466665-43-0 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)



RN 466665-44-1 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)




RN 466665-45-2 HCAPLUS  
CN Urea, N,N-diethyl-N'-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)




RN 466665-48-5 HCAPLUS  
CN Urea, N-[1-([2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidyl]-N'-methyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466665-39-4 HCAPLUS  
CN Urea, N-(2-chlorophenyl)-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]- (9CI)  
(CA INDEX NAME)



RN 466665-40-7 HCAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]- (9CI)  
(CA INDEX NAME)




RN 466665-41-8 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)




RN 466665-42-9 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466665-43-6 HCAPLUS  
CN Urea, N'-methyl-N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)




RN 466665-50-9 HCAPLUS  
CN Urea, N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)-N'-4-pyridinyl- (9CI)  
(CA INDEX NAME)



RN 466665-51-0 HCAPLUS  
CN Urea, N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)-N'-4-pyridinyl- (9CI)  
(CA INDEX NAME)




RN 466665-52-1 HCAPLUS  
CN Urea, N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidyl]-N-(phenylmethyl)-N'-4-pyridazinyl- (9CI)  
(CA INDEX NAME)



RN 466665-53-2 HCAPLUS  
CN Urea, N-[1-([5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-

Cc1c(Cc2cc(C(F)(F)F)ccc2)n[nH]1N(CCN(C(=O)Nc3ccncc3)Cc4ccccc4)c5ccccc5Cc1nc(C2=CC=C(C=C2)C(F)(F)F)c3nnc3CC4CCN(CC4)N(C5=CC=CC=C5)C(=O)Nc6ccsc6Cc1nc(CCN2CCCCC2NC(=O)Nc3ccoc3)c(c1)c4ccc(cc4)F(F)FCc1nnc(s1)NC(=O)N(Cc2ccccc2)C3CCN(CC3)CCc4c[nH]c5ccc(cc45)C(F)(F)F

PN 466665-62-3 HCAPLUS  
CN Urea, N-({4-aminophenyl)methyl}-N-[1-([5-methyl-2-([4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl)-N'-phenyl-9CI] (CA INDEX NAME)


Fc1ccc(cc1)c2nc(CCN3CCCCC3NC(=O)Cc4ccccc4)nn2Cc1nc(Cc2ccccc2N(C(=O)Nc3ccc(cc3)F)c4ccccc4)c5ccc(cc5F)c1[illegible]Cc1c[nH]c2c1c[nH]2c3ccc(cc3)[K+].[Cl-].C1CCN(CC1)C(=O)NCCc4cccnc4.C1=CC=C(C=C1)CC2=CC=CC=C2Cc1nc(Cc2ccccc2C(F)(F)F)c[nH]1C3CCN(CC3)C(=O)NCCc4cccnc4Cc1c(C2=CC=CC=C2C3=CC=CC=C3)nn(C4=CC=C(C=C4)C(F)(F)F)c1C5CCN(CC5)C(=O)NCC6=CC=CC=C6Cc1nc(Cc2ccccc2)nc1C3CCN(CC3)C(=O)N4CCOCC4Cc1c(Cc2ccccc2N3CCCCC3C(=O)N4CCCCC4)nn(c1-c1ccc(C)cc1)c1ccc(C)cc1

(Trifluoromethyl)phenyl]-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-81-0P, N-(2-chlorobenzyl)-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-82-2P, N-Cyclohexyl-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-83-3P, N-(Cyclohexylmethyl)-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-84-3P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-85-4P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-N-(3-phenylpropyl)-4-piperidinamine 46663-86-5P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-N-(4-methoxyphenyl)-4-piperidinamine 46663-87-6P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-N-(4-methoxybenzyl)-4-piperidinamine 46663-88-7P, 1-[[2-(4-(2-Chlorobenzyl)-5-methyl-1H-imidazol-4-yl)methyl)-4-piperidinamine 46663-89-8P, N-(2-chlorobenzyl)-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-90-1P, N-Cyclobutyl-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-91-2P, N-(Cyclobutylmethyl)-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-92-3P, N-(2-Chlorobenzyl)-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-93-4P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-N-(2-methoxybenzyl)-4-piperidinamine 46663-94-5P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-N-(2-methoxyphenyl)-4-piperidinamine 46663-96-7P, N-(3,5-Dichlorobenzyl)-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-97-8P, N-(3,5-Dichlorobenzylmethyl)-1-[[2-(4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46663-98-9P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-N-(3-nitrobenzyl)-4-piperidinamine 46664-01-1P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-N-(4-chlorobenzyl)-4-piperidinamine 46664-02-2P, 1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-N-(4-nitrobenzyl)-4-piperidinamine 46664-04-0P, N-(4-nitrobenzyl)-1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46664-05-1P, Methyl 4-[[1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]aminomethyl]benzoate 46666-07-3P, N-(4-[[1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]aminomethyl]benzoyl)benzylamine 46666-08-2P, N-(4-[[1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]aminomethyl]benzoyl)benzylamine 46666-09-3P, N-(Biphenyl-3-yl)methyl-1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46666-10-4P, N-(Biphenyl-4-yl)methyl-1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46666-11-5P, N-(4-(Phenoxymethyl)phenyl)-1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46666-13-1P, N-(4-(Phenoxymethyl)-4-piperidinamine 46666-13-1P, N-(Biphenyl)methyl-1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinamine 46666-15-3P, 4-[[1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]aminomethyl]benzotrile 46666-17-5P, N-(4-[[1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperidin-4-yl]amino]benzyl)-4-piperidinamine 46666-19-7P, 1-[[3-(2-Methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)propyl]piperidin-4-yl]-4-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]piperidin-4-yl]amino]piperidin-4-yl]amino]urea 46667-04-9P, N-1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]pyridin-3-ylmethylamine 46667-75-0P, N-1-[[2-(4-(Trifluoromethyl)phenyl)-5-methyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]pyridin-3-ynethylamine 46667-76-1P (Reactant for synthesis) (Synthetic preparation); PREP (Preparation); PACT (Reactant or reagent)


(intermediate; prepn. of imidazolylalkyl-aminopiperidines as HIV

inhibitors  
RN 466663-69-4 HCAPLUS  
CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[5-methyl-2-[[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-(9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466663-70-7 HCAPLUS  
CN 4-Piperidinone, 1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 466663-71-8 HCAPLUS  
CN 4-Piperidinamine, 1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 466663-72-9 HCAPLUS  
CN 4-Piperidinamine, 1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-N-[(2,4,6-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 466663-73-0 HCAPLUS  
CN 4-Piperidinamine, N-methyl-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 466663-74-1 HCAPLUS  
CN 4-Piperidinamine, N-ethyl-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466663-80-9 HCAPLUS  
CN 4-Piperidinamine, N-(cyclopropylmethyl)-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 466663-81-0 HCAPLUS  
CN 4-Piperidinamine, N-cyclopentyl-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 466663-82-1 HCAPLUS  
CN 4-Piperidinamine, N-cyclohexyl-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 466663-83-2 HCAPLUS  
CN 4-Piperidinamine, N-(cyclohexylmethyl)-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 466663-84-3 HCAPLUS  
CN 4-Piperidinamine, 1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466663-75-2 HCAPLUS  
CN 4-Piperidinamine, 1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 466663-76-3 HCAPLUS  
CN 4-Piperidinamine, N-(1-methylethyl)-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 466663-77-4 HCAPLUS  
CN 4-Piperidinamine, 1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 466663-78-5 HCAPLUS  
CN 4-Piperidinamine, N-butyl-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 466663-79-6 HCAPLUS  
CN 4-Piperidinamine, N-cyclopropyl-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466663-85-4 HCAPLUS  
CN 4-Piperidinamine, 1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 466663-86-5 HCAPLUS  
CN 4-Piperidinamine, N-(4-methoxyphenyl)-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 466663-87-6 HCAPLUS  
CN 4-Piperidinamine, N-[(4-methoxyphenyl)methyl]-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 466663-88-7 HCAPLUS  
CN 4-Piperidinamine, N-[(4-chlorophenyl)methyl]-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 466663-90-1 HCAPLUS  
CN 4-Piperidinamine, N-cyclobutyl-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466663-91-2 HCAPLUS  
CN 4-Piperidinamine, N-[(2,4-dichlorophenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466663-92-3 HCAPLUS  
CN 4-Piperidinamine, N-[(2-chlorophenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 466663-93-4 HCAPLUS  
CN 4-Piperidinamine, N-[(2-methoxyphenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466663-94-5 HCAPLUS  
CN 4-Piperidinamine, N-[(2-methylphenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466663-96-7 HCAPLUS


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-02-8 HCAPLUS  
CN 4-Piperidinamine, 1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 466664-04-0 HCAPLUS  
CN 4-Piperidinamine, N-[(4-aminophenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466664-05-1 HCAPLUS  
CN Benzoic acid, 4-[[1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 466664-07-3 HCAPLUS  
CN 4-Piperidinamine, N-[[4-(methylsulfonyl)phenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
CN 4-Piperidinamine, N-[(3,5-dichlorophenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466663-97-8 HCAPLUS  
CN 4-Piperidinamine, N-[(3,4-dichlorophenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 466663-98-9 HCAPLUS  
CN 4-Piperidinamine, N-[(3-methylphenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466663-99-0 HCAPLUS  
CN 4-Piperidinamine, 1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-N-[(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 466664-01-7 HCAPLUS  
CN 4-Piperidinamine, N-[(4-(dimethylamino)phenyl)methyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 466664-09-5 HCAPLUS  
CN 4-Piperidinamine, N-[(1,1'-biphenyl)-3-ylmethyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466664-11-9 HCAPLUS  
CN 4-Piperidinamine, 1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 466664-13-1 HCAPLUS  
CN 4-Piperidinamine, N-[(1,1'-biphenyl)-4-ylmethyl]-1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466664-15-3 HCAPLUS  
CN Benzonitrile, 4-[[1-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-4-yl)methyl]-4-piperidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 466664-17-5 HCAPLUS


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN 4-Piperidinamine, N-([2-methylpropyl]-1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 466664-19-7 HCAPLUS  
 CN 4-Piperidinamine, 1-[[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-N-[[4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 466664-21-1 HCAPLUS  
 CN Urea, N-[4-[[[1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]amino]methyl]phenyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 466671-74-9 HCAPLUS  
 CN 4-Pyridinemethanamine, N-[1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 466671-75-0 HCAPLUS  
 CN 3-Pyridinemethanamine, N-[1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

L24 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2001:827020 HCAPLUS  
 DI 136:294764  
 TI Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D2 and D3 receptors  
 AU Huang, Yunsheng; Luedtke, Robert R.; Freeman, Rebekah A.; Wu, Li; Mach, Robert H.  
 CS Department of Radiology-PET Center, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA  
 SO Bioorganic & Medicinal Chemistry (2003), 9(12), 3113-3122  
 CODEN: BMCEP; ISSN: 0968-0896  
 PB Elsevier Science Ltd.  
 DI Journal  
 LA English  
 OS CASREACT 136:294764  
 AB A series of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole derivs. was prepared and their affinity for dopamine D2 and D3 receptors was measured using in vitro binding assays. Several oxadiazole analogs were also prepared and tested for their affinity for dopamine D2 and D3 receptors. The results of receptor binding studies indicated that the incorporation of an imidazole moiety between the Ph ring and the basic nitrogen did not significantly increase the selectivity for dopamine D3 receptors, whereas the incorporation of an oxadiazole at the same region resulted in a total loss of affinity for both dopamine receptor subtype binding sites. The most selective compound in this series is 6,7-dimethoxy-2-[[2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydroisoquinoline, which has a D3 receptor affinity of 21 nM and a 7-fold selectivity for D3 vs. D2 receptors. The binding affinity for  $\alpha_1$  and  $\alpha_2$  receptors was also measured, and the results showed that several analogs were selective  $\alpha_1$  receptor ligands.  
 IT 407610-29-1P 407610-31-5P 407610-33-7P 407610-34-8P 407610-35-9P 407610-36-0P 407610-37-1P 407610-38-2P  
 RL PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and dopamine D2 and D3 receptor affinity of 2-(2,3-dimethoxyphenyl)-1H-imidazole-4-methanamine derivs.)  
 RN 407610-29-1 HCAPLUS  
 CN Isoquinoline, 2-[[2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 407610-31-5 HCAPLUS  
 CN Isoquinoline, 2-[[2-(5-bromo-2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 407610-33-7 HCAPLUS  
 CN Quinoline, 1-[[2-(5-bromo-2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


L24 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L24 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 407610-34-8 HCAPLUS  
 CN Piperidine, 1-[[2-(5-bromo-2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 407610-35-9 HCAPLUS  
 CN Piperidine, 1-[[2-(5-bromo-2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 407610-36-0 HCAPLUS  
 CN 4-Piperidinol, 1-[[2-(5-bromo-2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 407610-37-1 HCAPLUS  
 CN Benamide, N-[9-[[2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-9-azabicyclo[3.3.1]non-3-yl]-2,3-dimethoxy- (9CI) (CA INDEX NAME)

L24 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 407610-38-2 HCAPLUS

CN Benzanide, N-[9-([2-(5-bromo-2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-9-azabicyclo[3.3.1]non-3-yl]-2,3-dimethoxy- (9CI) (CA INDEX NAME)




IT 407610-30-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and dopamine D2 and D3 receptor affinity of 2-(5-bromo-2,3-dimethoxyphenyl)-1H-imidazole-4-methanamine derivs.)

RN 407610-30-4 HCAPLUS

CN Isoquinoline, 2-([2-(5-bromo-2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:701491 HCAPLUS

DN 128:3703

TI Preparation of 4-aryl substituted piperazinylmethyl phenylimidazoles as a new class of dopamine receptor subtype specific ligands  
THURKAUF, Andrew; HUTCHISON, Alan  
PA Neurogen Corp., USA  
SO U.S., 17 pp., Cont.-in-part of U.S. Ser. No. 313,435.

CODEN: UDXKAM

DT Patent

LA English

FAN.CNT 5

| PATENT NO.                                                                                                                                                                                                | KIND | DATE     | APPLICATION NO.  | DATE         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|--------------|
| US-----5681956                                                                                                                                                                                            | A    | 19971028 | 1995US-000401201 | 19950309 <-- |
| US-----5159083                                                                                                                                                                                            | A    | 19921027 | 1990US-000635256 | 19901128 <-- |
| US-----5428164                                                                                                                                                                                            | A    | 19950627 | 1993US-000081317 | 19931108 <-- |
| US-----5633376                                                                                                                                                                                            | A    | 19970527 | 1994US-000313435 | 19940927 <-- |
| US-----5633377                                                                                                                                                                                            | A    | 19970527 | 1995US-000462833 | 19950605 <-- |
| US-----5646281                                                                                                                                                                                            | A    | 19970708 | 1995US-000461135 | 19950605 <-- |
| US-----5656762                                                                                                                                                                                            | A    | 19970812 | 1995US-000461858 | 19950605 <-- |
| US-----5712392                                                                                                                                                                                            | A    | 19980127 | 1995US-000464548 | 19950605 <-- |
| CA-----2201140                                                                                                                                                                                            | A1   | 19960404 | 1995CA-002201140 | 19950926 <-- |
| WO-----9610018                                                                                                                                                                                            | A1   | 19960404 | 1995WO-US0012272 | 19950926 <-- |
| W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT |      |          |                  |              |
| RW: KE, MW, SD, SE, US, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG                                                            |      |          |                  |              |
| AU-----9537259                                                                                                                                                                                            | A    | 19960419 | 1995AU-000037259 | 19950926 <-- |
| AU-----705585                                                                                                                                                                                             | B2   | 19950527 |                  |              |
| EP-----783494                                                                                                                                                                                             | A1   | 19970716 | 1995EP-000935121 | 19950926 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE                                                                                                                                         |      |          |                  |              |
| CN-----1158608                                                                                                                                                                                            | A    | 19970903 | 1995CN-000195289 | 19950926 <-- |
| CN-----1092643                                                                                                                                                                                            | B    | 20021016 |                  |              |
| HU-----76928                                                                                                                                                                                              | A2   | 19980128 | 1997HU-000001497 | 19950926 <-- |
| JP-----10501819                                                                                                                                                                                           | T    | 19980217 | 1995JP-000511959 | 19950926 <-- |
| JP-----2927967                                                                                                                                                                                            | B2   | 19990728 |                  |              |
| BR-----9509101                                                                                                                                                                                            | A    | 19980714 | 1995BR-000009101 | 19950926 <-- |
| CA-----2205998                                                                                                                                                                                            | A1   | 19960530 | 1995CA-002205998 | 19951122 <-- |
| CA-----2205998                                                                                                                                                                                            | C    | 20020716 |                  |              |
| WO-----9616040                                                                                                                                                                                            | A1   | 19960530 | 1995WO-US0015262 | 19951122 <-- |
| W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT |      |          |                  |              |
| RW: KE, LS, MW, SD, SE, US, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG                                                        |      |          |                  |              |
| AU-----9643689                                                                                                                                                                                            | A    | 19960617 | 1996AU-000043689 | 19951122 <-- |
| EP-----793653                                                                                                                                                                                             | A1   | 19970910 | 1995EP-000942473 | 19951122 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE                                                                                                                                     |      |          |                  |              |
| JP-----10502670                                                                                                                                                                                           | T    | 19980310 | 1995JP-000517074 | 19951122 <-- |
| JP-----2941950                                                                                                                                                                                            | B2   | 19990830 |                  |              |
| CN-----1177349                                                                                                                                                                                            | A    | 19980325 | 1995CN-000197446 | 19951122 <-- |
| CN-----1088062                                                                                                                                                                                            | B    | 20020724 |                  |              |
| BR-----9509760                                                                                                                                                                                            | A    | 19980630 | 1995BR-000009760 | 19951122 <-- |
| WO-----9701423                                                                                                                                                                                            | A    | 19970523 | 1997WO-000001423 | 19970325 <-- |
| US-----4068251                                                                                                                                                                                            | A    | 20000530 | 1997US-000858961 | 19970521 <-- |
| US-----6358955                                                                                                                                                                                            | B1   | 20020319 | 2000US-000497988 | 20000204 <-- |
| US-----2002143044                                                                                                                                                                                         | A1   | 20021003 | 2002US-000100691 | 20020318 <-- |
| US-----6797824                                                                                                                                                                                            | B2   | 20040528 |                  |              |
| PRAI 1990US-000635256                                                                                                                                                                                     | A2   | 19901228 | <--              |              |
| 1993US-000081317                                                                                                                                                                                          | A2   | 19931108 | <--              |              |
| 1994US-000313435                                                                                                                                                                                          | A2   | 19940927 | <--              |              |
| 1991WO-US0009816                                                                                                                                                                                          | W    | 19911223 | <--              |              |
| 1994US-000344154                                                                                                                                                                                          | B1   | 19941123 | <--              |              |
| 1994US-000344552                                                                                                                                                                                          | A    | 19941123 | <--              |              |
| 1995US-000401201                                                                                                                                                                                          | A    | 19950309 | <--              |              |

L24 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

1995US-000462833 A1 19950605 <--  
1995WO-US0012272 W 19950926 <--  
1995WO-US0015262 W 19951122 <--  
1997US-000858961 A1 19970521 <--  
2000US-000497988 A1 20000204 <--

OS MARPAT 128:3703

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The title compds. [I; R1, T = H, halo, OH, etc.; M = II, III (wherein R2 = H, Cl-6 alkyl; R1R2 = (CH2)n, n = 1-3; X, Z = H, halo, OH, etc.; Y = H, halo, NH2, etc.; R3 = H, Cl-6 alkyl; R3R4 = (CH2)m, m = 3-4; R4, R5 = H, Cl-6 alkyl, phenylalkyl, etc.; R2R5 = (CH2)2; q = 2-3; NR4R5 = (un)substituted 2-(1,2,3,4-tetrahydroisoquinolinyl), IV (wherein W = N, CH; R7 = H, Ph, pyridyl, etc.; WR7 = O, S; p = 1-3)] and their salts, highly selective partial agonists or antagonists at brain dopamine receptor subtypes useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism, and in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents, were prepared. Thus, treatment of 2-phenyl-4(5)-hydroxymethylimidazole with SOCl2 followed by addition of CHCl3, 1-(5-methoxy-2-pyrimidinyl)piperazine and Et3N afforded 864 V. For example, compound Vt.8CI showed Ki of 2.7 nM against D4 receptor binding.

IT 144649-79-6P 144649-80-9P 144649-82-1P

144649-98-9P 178928-64-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 4-aryl substituted piperazinylmethyl phenylimidazoles as a new class of dopamine receptor subtype specific ligands)

RN 144649-79-6 HCAPLUS


CN Piperidine, 1-([2-(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 144649-80-9 HCAPLUS

CN Piperidine, 4-phenyl-1-([2-(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 144649-82-1 HCAPLUS

CN Isoquinoline, 2-([2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)


L24 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● 2 HCl

RN 144649-98-9 HCAPLUS


CN Piperidine, 1-([2-(5-chloro-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 178928-64-8 HCAPLUS

CN Piperidine, 1-([2-(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L24 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN  
 AN 1997:372672 HCAPLUS  
 DN 127:65785  
 TI Preparation of aminomethyl-, piperazinomethyl- and piperidinomethyl-substituted phenylimidazoles as a new class of dopamine receptor subtype ligands  
 IN Thurnkauf, Andrew; Hutchison, Alan  
 PA Neurogen Corporation, USA  
 SO U.S., 16 pp., Cont.-in-part of U.S. 5,428,164.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CMI 5


| PATENT NO.     | KIND | DATE     | APPLICATION NO.  | DATE         |
|----------------|------|----------|------------------|--------------|
| US-----5633376 | A    | 19970527 | 1994US-000313435 | 19940927 <-- |
| US-----5159083 | A    | 19921027 | 1990US-000635256 | 19901228 <-- |
| US-----5428164 | A    | 19950627 | 1993US-000081317 | 19931108 <-- |
| US-----5681956 | A    | 19971028 | 1995US-000401201 | 19950309 <-- |
| US-----5646279 | A    | 19970708 | 1995US-000457036 | 19950601 <-- |
| US-----5646280 | A    | 19970708 | 1995US-000457989 | 19950601 <-- |
| US-----5633377 | A    | 19970527 | 1995US-000462833 | 19950605 <-- |
| US-----5646281 | A    | 19970708 | 1995US-000461135 | 19950605 <-- |
| US-----5656762 | A    | 19970812 | 1995US-000461858 | 19950605 <-- |
| US-----5712392 | A    | 19980127 | 1995US-000464548 | 19950605 <-- |
| CA-----2201140 | A1   | 19960404 | 1995CA-002201140 | 19950926 <-- |
| WO-----9610018 | A1   | 19960404 | 1995WO-US0012272 | 19950926 <-- |

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CE, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT  
 RW: KE, MW, SD, SE, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU-----9537259 A 19960419 1995AU-000037259 19950926 <--  
 AU-----705585 B2 19990527 19990527 <--  
 EP-----783494 A1 19970716 1995EP-000935121 19950926 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE  
 CN-----1158608 A 19970903 1995CN-000195289 19950926 <--  
 CN-----1092643 B 20021016 <--  
 HU-----76928 A2 19980128 1997HU-000001497 19950926 <--  
 JP-----10501819 T 19980217 1995JP-000511959 19950926 <--  
 JP-----2927967 B2 19990728 <--  
 BR-----9509101 A 19980714 1995BR-000009101 19950926 <--  
 NO-----9701423 A 19970523 1997NO-000001423 19970325 <--  
 US-----6069251 A 20000530 1997US-000859861 19970521 <--  
 US-----6358955 B1 20020319 2000US-000497988 20000204 <--  
 US-----2002143044 A1 20021003 2002US-000100691 20020318 <--  
 US-----6797824 B2 20040928 <--  
 PRAI 1994US-000635256 A2 19901228 <--  
 1993US-000081317 A2 19931108 <--  
 1991WO-US0009816 W 19911223 <--  
 1994US-000313435 A2 19940927 <--  
 1994US-000344154 B1 19941123 <--  
 1994US-000344552 B1 19941123 <--  
 1995US-000401201 A 19950309 <--  
 1995US-000462833 A1 19950605 <--  
 1995WO-US0012272 W 19950926 <--  
 1997US-000859861 A1 19970521 <--  
 2000US-000497988 A1 20000204 <--  
 GI MARPAT 1:27:65785




L24 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)




● 2 HCl

RN 146649-98-9 HCAPLUS  
 CN Piperidine, 1-[(2-(5-chloro-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 178928-64-8 HCAPLUS  
 CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 191529-20-1 HCAPLUS  
 CN Piperidine, 1-[(2-(5-chloro-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



L24 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)


AB The title compds. [I; R1, T = H, halo, OH, etc.; X = H, halo, OH, etc.; Y = H, halo, OH, etc.; R4, R5 = C1-6 alkyl, phenyl(C1-6)alkyl; NR4R5 = (un)substituted 2-(1,2,3,4-tetrahydroisoquinolinyl), highly selective partial agonists or antagonists at brain dopamine receptor subtypes, and useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism, were prepared. Thus, treatment of 2-(5-bromo-2-methoxyphenyl)-5-hydroxymethyl-imidazole with SOCl2 followed by reaction of the resulting intermediate with Me2NH in iPrOH/CH2Cl2 afforded 1,2HCl [R1, X = H; T = MeO; Y = Br; R4 = R5 = Me] which showed IC50 of 0.900 μM against D2 and D3 receptor binding. Furthermore compds. I may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

IT 146649-79-6P 146649-80-9P 146649-82-1P  
 146649-98-9P 178928-64-8P 191529-20-1P  
 RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 [preparation of aminomethyl-, piperazinomethyl- and piperidinomethyl-substituted phenylimidazoles as a new class of dopamine receptor subtype ligands]  
 RN 146649-79-6 HCAPLUS  
 CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 146649-80-9 HCAPLUS  
 CN Piperidine, 4-phenyl-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 146649-82-1 HCAPLUS  
 CN Isoquinoline, 2-[(2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-3,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)


L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN

AN 1996:467020 HCAPLUS  
 DN 125:114630  
 TI Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands  
 IN Thurnkauf, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.  
 PA Neurogen Corporation, USA  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIIXD2  
 DT Patent  
 LA English  
 FAN.CMI 5

| PATENT NO.     | KIND | DATE     | APPLICATION NO.  | DATE         |
|----------------|------|----------|------------------|--------------|
| WO-----9616040 | A1   | 19960530 | 1995WO-US0015262 | 19951122 <-- |


W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CE, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT  
 RW: KE, LG, MW, SD, SE, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US-----5681956 A 19971028 1995US-000401201 19950309 <--  
 US-----5633377 A 19970527 1995US-000462833 19950605 <--  
 US-----5646281 A 19970708 1995US-000461135 19950605 <--  
 US-----5656762 A 19970812 1995US-000461858 19950605 <--  
 US-----5712392 A 19980127 1995US-000464548 19950605 <--  
 AU-----9643689 A 19960617 1996AU-000043689 19951122 <--  
 EA-----9509910 A 19970822 1995EA-000009911 19951122 <--  
 ZA-----9509911 A 19970822 1995ZA-000009911 19951122 <--  
 EP-----793653 A1 19970910 1995EP-000942473 19951122 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
 EA-----9707500 A 19980223 1997EA-000007500 19951122 <--  
 JP-----10502670 T 19980310 1995JP-000517074 19951122 <--  
 JP-----2941950 B2 19990830 <--  
 BR-----9509760 A 19980630 1995BR-000009760 19951122 <--  
 US-----6069251 A 20000530 1997US-000859861 19970521 <--  
 US-----6358955 B1 20020319 2000US-000497988 20000204 <--  
 US-----2002143044 A1 20021003 2002US-000100691 20020318 <--  
 US-----6797824 B2 20040928 <--  
 PRAI 1994US-000344154 A2 19941123 <--  
 1994US-000344552 A2 19941123 <--  
 1995US-000401201 A2 19950309 <--  
 1995US-000635256 A2 19901228 <--  
 1993US-000081317 A2 19931108 <--  
 1994US-000313435 A2 19940927 <--  
 1995US-000462833 A1 19950605 <--  
 1995WO-US0015262 W 19951122 <--  
 1997US-000859861 A1 19970521 <--  
 2000US-000497988 A1 20000204 <--  
 OS GI MARPAT 125:114630




AB Disclosed are compds. (I), wherein R1 represents optionally substituted aryl, heteroaryl, alkyl, or cycloalkyl groups; X, Y, and Z are optionally substituted nitrogen or carbon atoms; R3 and R4 are organic or inorg. substituents which may together form ring structures; m is zero, one or two; and R5 and R6 are organic or inorg. substituents; and the pharmaceutically acceptable addition salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Specifically, 2-phenyl-4-(5)-1-(4-(2-pyrimidinyl)piperazin-1-yl)methylimidazole dihydrochloride was prepared and was shown to bind to the dopamine D4

L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 receptor site (K<sub>i</sub> = 1033, 8200; 2.7 for D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub> binding sites, resp.).  
 IT 144649-79-6P 144649-80-9P 144649-81-OP  
 144649-82-1P 144649-98-9P 178928-64-8P  
 178928-66-OP 179332-10-4P 179332-11-7P  
 179332-13-9P 179332-14-OP 179332-15-1P  
 179332-16-2P 179332-17-3P 179332-18-4P  
 179332-19-5P 179332-27-5P 179332-28-6P  
 179332-29-7P 179332-30-OP 179332-31-1P  
 179332-32-2P 179332-35-5P 179332-36-6P  
 179332-44-6P 179332-63-9P 179332-64-OP  
 179332-68-4P 179332-78-6P 179332-81-1P  
 179332-92-4P 179332-98-OP 179333-00-7P  
 179333-17-6P 179333-38-1P 179333-39-2P  
 179333-40-5P 179333-41-6P 179333-42-7P  
 179333-43-8P 179333-49-4P 179333-50-7P  
 179333-62-1P 179333-69-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazole derivs. as dopamine receptor partial agonists or  
 antagonists for memory enhancement and treatment of schizophrenia and  
 depression and Parkinsonism)  
 RN 144649-79-6 HCAPLUS  
 CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-,  
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 144649-80-9 HCAPLUS  
 CN Piperidine, 4-phenyl-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-,  
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 144649-81-0 HCAPLUS  
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(2-phenyl-1H-imidazol-4-yl)methyl]-,  
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179332-11-7 HCAPLUS  
 CN Piperidine, 1-[(2-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-,  
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179332-13-9 HCAPLUS  
 CN Piperidine, 1-[(2-(2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-,  
 dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 179332-14-0 HCAPLUS  
 CN Piperidine, 1-[(2-(3-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-,  
 dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 179332-15-1 HCAPLUS  
 CN Piperidine, 1-[(2-(3-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-,  
 dihydrochloride (9CI) (CA INDEX NAME)

L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 RN 144649-82-1 HCAPLUS  
 CN Isoquinoline, 2-[(2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-  
 tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 144649-98-9 HCAPLUS  
 CN Piperidine, 1-[(2-(5-chloro-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-  
 phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 178928-64-8 HCAPLUS  
 CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI)  
 (CA INDEX NAME)



● 2 HCl

RN 178928-66-0 HCAPLUS  
 CN Pyridine, 2-[1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-,  
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 179332-10-6 HCAPLUS  
 CN Piperidine, 1-[(2-(4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-,  
 dihydrochloride (9CI) (CA INDEX NAME)



L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 179332-16-2 HCAPLUS  
 CN Piperidine, 1-[(2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-,  
 dihydrochloride (9CI) (CA INDEX NAME)



RN 179332-17-3 HCAPLUS  
 CN Piperidine, 1-[(2-(2-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-,  
 (2S)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CFRN 179332-16-2  
 CMF C21 H22 F N3




CM 2

CFRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 179332-18-4 HCAPLUS  
 CN Piperidine, 1-[(2-(2-methylphenyl)-1H-imidazol-4-yl)methyl]-4-  
 (phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 179332-19-5 HCAPLUS  
 CN Piperidine, 1-[(2-(5-ethyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-  
 phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● 2 HCl


RN 179332-27-5 HCAPLUS  
 CN Piperidine, 4-(4-fluorophenyl)-1-((2-phenyl-1H-imidazol-4-yl)methyl)-  
 (9CI) (CA INDEX NAME)



RN 179332-28-6 HCAPLUS  
 CN Piperidine, 4-(4-fluorophenyl)-1-((2-phenyl-1H-imidazol-4-yl)methyl)-,  
 (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 179332-27-5  
 CMF C21 H22 F N3




CM 2

CRN 110-16-7  
 CMF C4 H4 O4


Double bond geometry as shown.



RN 179332-29-7 HCAPLUS  
 CN Piperidine, 1-([2-(3-fluorophenyl)-1H-imidazol-4-yl]methyl)-4-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)




L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 179332-36-6 HCAPLUS  
 CN Piperidine, 1-([2-(2-fluorophenyl)-1H-imidazol-4-yl]methyl)-4-  
 (phenylmethyl)-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 179332-35-5  
 CMF C22 H24 F N3




CM 2

CRN 110-16-7  
 CMF C4 H4 O4


Double bond geometry as shown.



RN 179332-44-6 HCAPLUS  
 CN Piperidine, 1-([1-(1-methyl-2-phenyl-1H-imidazol-5-yl)methyl]-4-  
 (phenylmethyl)- (CA INDEX NAME)



RN 179332-63-9 HCAPLUS  
 CN Piperidine, 1-([1-(2-phenyl-1H-imidazol-4-yl)ethyl]-4-(phenylmethyl)-,  
 dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 179332-64-0 HCAPLUS  
 CN Piperidine, 1-([2-(1-naphthalenyl)-1H-imidazol-4-yl]methyl)-4-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)

L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 179332-30-0 HCAPLUS  
 CN Piperidine, 1-([2-(3-fluorophenyl)-1H-imidazol-4-yl]methyl)-4-  
 (phenylmethyl)-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 179332-29-7  
 CMF C22 H24 F N3




CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 179332-31-1 HCAPLUS  
 CN Piperidine, 1-([2-(4-fluorophenyl)-1H-imidazol-4-yl]methyl)-4-  
 (phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 179332-32-2 HCAPLUS  
 CN Piperidine, 4-([4-(4-fluorophenyl)methyl]-1-([2-phenyl-1H-imidazol-4-  
 yl]methyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179332-35-5 HCAPLUS  
 CN Piperidine, 1-([2-(2-fluorophenyl)-1H-imidazol-4-yl]methyl)-4-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)


L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 179332-68-4 HCAPLUS  
 CN Piperidine, 1-([2-(2-naphthalenyl)-1H-imidazol-4-yl]methyl)-4-  
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 179332-78-6 HCAPLUS  
 CN Pyrazine, [4-([4-(phenylmethyl)-1-piperidinyl]methyl)-1H-imidazol-2-yl]-  
 (9CI) (CA INDEX NAME)



RN 179332-81-1 HCAPLUS  
 CN Piperidine, 4-(phenylmethyl)-1-([2-(2-thienyl)-1H-imidazol-4-yl]methyl)-  
 (9CI) (CA INDEX NAME)




RN 179332-92-4 HCAPLUS  
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[1-oxo-3-(2-phenyl-1H-imidazol-4-yl)-2-  
 propenyl]- (9CI) (CA INDEX NAME)




RN 179332-98-0 HCAPLUS  
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[3-(2-phenyl-1H-imidazol-4-yl)propyl]-  
 (9CI) (CA INDEX NAME)


L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 179333-00-7 HCAPLUS  
CN Piperidine, 1-([2-(2-cyclohexyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-9CI) (CA INDEX NAME)




RN 179333-17-6 HCAPLUS  
CN Piperidine, 1-([2-(2-phenyl-1H-imidazol-4-yl)carbonyl]-4-(phenylmethyl)-monohydrochloride) (CA INDEX NAME)




● HCl

RN 179333-38-1 HCAPLUS  
CN Piperidine, 1-([2-(4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-9CI) (CA INDEX NAME)




RN 179333-39-2 HCAPLUS  
CN Piperidine, 1-([2-(4-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-9CI) (CA INDEX NAME)




RN 179333-40-5 HCAPLUS  
CN Piperidine, 1-([2-(2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-9CI) (CA INDEX NAME)


L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 179333-62-1 HCAPLUS  
CN Piperidine, 1-([2-(2-phenyl-1H-imidazol-4-yl)ethyl]-4-(phenylmethyl)-9CI) (CA INDEX NAME)




RN 179333-69-8 HCAPLUS  
CN Piperidine, 1-([2-(2-phenyl-1H-imidazol-4-yl)carbonyl]-4-(phenylmethyl)-9CI) (CA INDEX NAME)




L24 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 179333-41-6 HCAPLUS  
CN Piperidine, 1-([2-(3-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-9CI) (CA INDEX NAME)




RN 179333-42-7 HCAPLUS  
CN Piperidine, 1-([2-(2-methylphenyl)-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-9CI) (CA INDEX NAME)



RN 179333-43-8 HCAPLUS  
CN Piperidine, 1-([2-(5-ethyl-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-9CI) (CA INDEX NAME)



RN 179333-49-4 HCAPLUS  
CN Piperidine, 1-([2-(4-fluorophenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-9CI) (CA INDEX NAME)







RN 179333-50-7 HCAPLUS  
CN Piperidine, 1-([2-(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-9CI) (CA INDEX NAME)

L24 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:446484 HCAPLUS  
DN 125:114617  
TI Preparation of 2-phenyl-4(5)-aminomethylimidazoles as dopamine receptor subtype specific ligands  
IN Thirukaur, Andrew; Hutchison, Alan  
PA Neurogen Corporation, USA  
SO PCT Int. Appl., 56 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN: CNT 5

| PATENT NO.                                                                                                                                                                                                | KIND | DATE     | APPLICATION NO.  | DATE         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|--------------|
| PI WO-----9610018                                                                                                                                                                                         | A1   | 19960404 | 1995WO-00012272  | 19950926 <-- |
| M: AM, AI, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT |      |          |                  |              |
| PW: KE, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PE, SE, BF, BJ, CF, CG, CI, CM, CA, GH, ML, MR, NE, SN, TD, TG                                                            |      |          |                  |              |
| US-----5633376                                                                                                                                                                                            | A    | 19970527 | 1994US-000313435 | 19940927 <-- |
| US-----5681956                                                                                                                                                                                            | A    | 19971028 | 1995US-000401201 | 19950309 <-- |
| AU-----9537259                                                                                                                                                                                            | A    | 19960419 | 1995AU-000037259 | 19950926 <-- |
| AU-----705585                                                                                                                                                                                             | B2   | 19990527 |                  |              |
| EP-----783494                                                                                                                                                                                             | A1   | 19970716 | 1995EP-000935121 | 19950926 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE                                                                                                                                         |      |          |                  |              |
| JP-----10501819                                                                                                                                                                                           | T    | 19980217 | 1995JP-000511959 | 19950926 <-- |
| JP-----2927967                                                                                                                                                                                            | B2   | 19990728 |                  |              |
| BR-----9509101                                                                                                                                                                                            | A    | 19980714 | 1995BR-000009101 | 19950926 <-- |
| NO-----9701423                                                                                                                                                                                            | A    | 19970523 | 1997NO-000001423 | 19970325 <-- |
| PRAI 1994US-000313435                                                                                                                                                                                     | A2   | 19940927 | <--              |              |
| 1995US-000401201                                                                                                                                                                                          | A2   | 19950309 | <--              |              |
| 1990US-000635256                                                                                                                                                                                          | A2   | 19901228 | <--              |              |
| 1993US-000081317                                                                                                                                                                                          | A2   | 19931108 | <--              |              |
| 1995WO-00012272                                                                                                                                                                                           | W    | 19950926 | <--              |              |
| OS CASREACT 125:114617; MARPAT 125:114617                                                                                                                                                                 |      |          |                  |              |
| GI                                                                                                                                                                                                        |      |          |                  |              |




AB The title compds. (I; R1, R2, X, Z = H, halo, OH, etc.; Y = H, halo, amino, C1-6 alkyl; M = (N-substituted) imidazole; R3 H, C1-6 alkyl; R4, R5 = H, C1-6 alkyl, phenylalkyl, pyridylalkyl; R3R4 = (CH2)n (wherein n = 3, 4); NR4R5 = piperidino, piperasino, 2-(1,5,3,4-tetrahydroisoquinolyl), etc.), useful in the diagnosis and treatment of CNS disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism, were prepared Reaction of 5-bromo-2-methoxybenzonitrile with NH3 followed by cyclization of benzamide II with 1,3-dihydroxyacetone dimer and reaction of the imidazole III with Me2NH afforded the desired product IV.2HCl which showed IC50 of 0.9 μM against dopamine D1 and D3 receptor binding  
IT 144649-79-6P 144649-80-9P 144649-81-0P  
144649-82-1P 144649-98-9P 178928-64-8P

L24 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


178928-65-9P 178928-66-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 2-phenyl-4(5)-aminomethylimidazoles as dopamine receptor subtype specific ligands)

RN 144649-79-6 HCAPLUS  
 CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 144649-80-9 HCAPLUS  
 CN Piperidine, 4-phenyl-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 144649-81-0 HCAPLUS  
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 144649-82-1 HCAPLUS  
 CN Isoquinoline, 2-[(2-(2,3,4-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L24 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


L24 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 144649-98-9 HCAPLUS  
 CN Piperidine, 1-[(2-(5-chloro-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 178928-64-8 HCAPLUS  
 CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 178928-65-9 HCAPLUS  
 CN Piperidine, 1-[(2-(2,3-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-4-(2-methoxyphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 178928-66-0 HCAPLUS  
 CN Pyridine, 2-[1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


L24 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 1995:592275 HCAPLUS  
 EN 123:55767  
 IT 2-Phenyl-4-(aminomethyl)imidazoles as Potential Antipsychotic Agents. Synthesis and Dopamine D2 Receptor Binding  
 AU Thurkauf, Andrew; Hutchison, Alan; Peterson, John; Cornfield, Linda; Meade, Robin; Huston, Kevin; Harris, Kristine; Ross, Philip C.; Gerber, Karen; Ramabhadran, T. V.  
 CS Department of Chemistry, Neurogen Corporation, Branford, CT, 06405, USA  
 SO Journal of Medicinal Chemistry (1995), 38(12), 2251-5  
 CODEN: JMCMAH; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB A series of 2-phenyl-4-(aminomethyl)imidazoles (1H-imidazole-4-methanamines) were designed as conformationally restricted analogs of the dopamine D2 selective benzamide antipsychotics. The title compds. were synthesized and tested for blockade of [3H]YM-09151 binding in cloned African green monkey dopamine D2 receptor preps. The binding affinity data thus obtained were compared against that of the benzamides and a previously described series of 2-phenyl-5-(aminomethyl)pyrroles.  
 IT 164670-70-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of 1H-imidazole-4-methanamines as antipsychotics)  
 RN 164670-70-6 HCAPLUS  
 CN Pyridine, 1,2,3,4-tetrahydro-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 164670-63-7P 164670-65-9P 164670-66-0P  
 164670-67-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of 1H-imidazole-4-methanamines as antipsychotics)  
 RN 164670-63-7 HCAPLUS  
 CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 164670-65-9 HCAPLUS  
 CN 1H-9benzimidazol-2-one, 1,3-dihydro-1-[1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-piperidinyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 164670-64-8  
 CMF C22 H23 N5 O

L24 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



CM 2


CRH 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



RN 164670-66-0 HCAPLUS


CN 1,3,8-Triazaspiro[4.5]decan-4-one, 1-phenyl-8-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 164670-67-1 HCAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-4-phenyl-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L24 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN

RN 1992:651350 HCAPLUS

DN 117:251350

TI Preparation of (aminomethyl)phenylimidazoles as dopamine receptor ligands

IN Thurnkauf, Andrew T.; Hutchison, Alan J.

PA Neurogen Corp., USA

SO PCT Int. Appl., 44 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN, CNT 5

| PATENT NO.                                                    | KIND | DATE         | APPLICATION NO.  | DATE         |
|---------------------------------------------------------------|------|--------------|------------------|--------------|
| WO-----9212134                                                | A2   | 19920723     | 1991WO-US0009816 | 19911223 <-- |
| WO-----9212134                                                | A3   | 19920820     |                  |              |
| W: CA, JP, US                                                 |      |              |                  |              |
| RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE    |      |              |                  |              |
| US-----5159083                                                | A    | 19921027     | 1990US-000635256 | 19901228 <-- |
| CA-----2098301                                                | A1   | 19920629     | 1991CA-002098301 | 19911223 <-- |
| CA-----2098301                                                | C    | 20011204     |                  |              |
| JP-----06504054                                               | T    | 19940512     | 1991JP-000503226 | 19911223 <-- |
| JP-----2798095                                                | B2   | 19980917     |                  |              |
| EP-----440075                                                 | A1   | 19950301     | 1992EP-000903112 | 19911223 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE |      |              |                  |              |
| US-----5428164                                                | A    | 19950627     | 1993US-00081317  | 19931108 <-- |
| US-----5632377                                                | A    | 19970527     | 1995US-000462833 | 19950605 <-- |
| US-----5646281                                                | A    | 19970708     | 1995US-000461135 | 19950605 <-- |
| US-----5656762                                                | A    | 19970812     | 1995US-000461858 | 19950605 <-- |
| US-----5712392                                                | A    | 19980127     | 1995US-000464548 | 19950605 <-- |
| US-----6069251                                                | A    | 20000530     | 1997US-000839861 | 19970521 <-- |
| US-----6358955                                                | B1   | 20020319     | 2000US-000497988 | 20000204 <-- |
| US---2002143044                                               | A1   | 20021003     | 2002US-000100691 | 20020318 <-- |
| US---6797824                                                  | B2   | 20040928     |                  |              |
| PRAI 1990US-000635256                                         | A2   | 19901228 <-- |                  |              |
| 1991WO-US0009816                                              | W    | 19911223 <-- |                  |              |
| 1993US-00081317                                               | A2   | 19931108 <-- |                  |              |
| 1994US-000344154                                              | B1   | 19941123 <-- |                  |              |
| 1995US-000462833                                              | A1   | 19950605 <-- |                  |              |
| 1997US-000839861                                              | A1   | 19970521 <-- |                  |              |
| 2000US-000497988                                              | A1   | 20000504 <-- |                  |              |
| OS MAPPAT 117:251350                                          |      |              |                  |              |
| GI                                                            |      |              |                  |              |



AB Title comps. [I; R1, T = H, halo, OH, alkyl, alkoxy; M = Q1, Q2; R2 = H, alkyl; R1R2 = CH2, CH2CH2, CH2CH2CH2; X1Z = H, halo, OH, alkyl, alkoxy,

L24 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)

502R6; Y = H, halo, amino, alkyl; R3 = H, alkyl; R3R4 = (CH2)3, (CH2)4; R4, R5 = H, alkyl, phenylalkyl, pyridylalkyl; R2R5 = CH2CH2, (CH2)3; NR4R5 = (substituted) 2-(1,2,3,4-tetrahydroisoquinidinyl) Q3; M = N, CH; R7 = H, (substituted) Ph, pyridyl, pyrimidinyl; WR7 = O, S; n = 1-3], were prepd. Thus, 5-bromo-2-methoxybenzonitrile (prepn. from 5-bromo-2-anisaldehyde given) was stirred with 3 Å sieves in MeOH contg. HCl to give a residue which was heated with NH3 in MeOH at 80° in a sealed tube to give 5-bromo-2-methoxybenzimidine. The latter was heated with 1,3-dihydroxyacetone dimer, NH4Cl, and conc. aq. NH3 in THF to give 2-(5-bromo-2-methoxyphenyl)-5-hydroxymethylimidazole. The latter was heated with SOCl2 to give a residue which was heated with Me2NH in CH2Cl2/Me2CHOH to give a residue. This was treated with HCl to give title compd. II. 1 in rat striatal homogenates showed IC50 of 0.011-0.620 μM for D2 and D3 receptor binding activity.

II 144649-79-6P 144649-80-9P 144649-81-0P


144649-82-1P 144649-98-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as dopamine receptor ligand)

RN 144649-79-6 HCAPLUS


CN Piperidine, 1-[(2-phenyl-1H-imidazol-4-yl)methyl]-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 144649-80-9 HCAPLUS


CN Piperidine, 4-phenyl-1-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 144649-81-0 HCAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-2-[(2-phenyl-1H-imidazol-4-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 144649-82-1 HCAPLUS

CN Isoquinoline, 2-[(1,2,3,4-dimethoxyphenyl)-1H-imidazol-4-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)


L24 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



● 2 HCl

RN 144649-98-9 HCAPLUS

CN Piperidine, 1-[(2-(5-chloro-2-methoxyphenyl)-1H-imidazol-4-yl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

=> b hcao  
FILE 'HCAOLD' ENTERED AT 18:20:22 ON 03 MAR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING  
FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d all 126 tot

L26 ANSWER 1 OF 1 HCAOLD COPYRIGHT 2008 ACS on STN  
AN CAS1:487d CAOLD  
TI diphenyldihydro- and -tetrahydroglyoxalin-4-one  
AU Goodman, Louis S.  
DT Patent  
PATENT NO. KIND DATE  
-----  
PI US-----2744852 1956  
IT 3254-83-1 13197-48-3 13213-81-1 16459-51-1 21083-47-6  
114840-67-4 132468-41-8

=> b reg;d ide can l27  
FILE 'REGISTRY' ENTERED AT 18:20:41 ON 03 MAR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2008 HIGHEST RN 1006303-40-7  
DICTIONARY FILE UPDATES: 2 MAR 2008 HIGHEST RN 1006303-40-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

L27 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 132468-41-8 REGISTRY  
ED Entered STN: 08 Mar 1991  
CN Piperidine, 1-[2-[2-phenylimidazol-4(or 5)-yl]ethyl]- (6CI) (CA INDEX  
NAME)  
MF C16 H21 N3  
SR CAOLD  
LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CHEMCATS, USPATOLD  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 51:2050

REFERENCE 2: 51:2049

=> d his

(FILE 'HOME' ENTERED AT 17:28:05 ON 03 MAR 2008)

FILE 'HCAPLUS' ENTERED AT 17:28:41 ON 03 MAR 2008

L1 1 US20060154917/PN

FILE 'REGISTRY' ENTERED AT 17:28:58 ON 03 MAR 2008

FILE 'HCAPLUS' ENTERED AT 17:28:58 ON 03 MAR 2008

L2 TRA L1 1- RN : 227 TERMS

FILE 'REGISTRY' ENTERED AT 17:28:58 ON 03 MAR 2008

L3 227 SEA L2

L4 191 L3 AND NCNC2/ES

L5 STR

L6 1 L5

L7 908950 NCNC2/ES

L8 3 L5 SAM SUB=L7

L9 739 L5 FULL SUB=L7

SAV TEM J401C1GXIII/A L9

L10 161 L9 AND L3

L11 578 L9 NOT L10

FILE 'HCAPLUS' ENTERED AT 17:33:37 ON 03 MAR 2008

L12 1 L10

L13 66 L11

L14 43 L13 AND (PD<=20030703 OR AD<=20030703 OR PRD<=20030703)

L15 23 L13 AND PD<=20020703

L16 20 L14 NOT L15

SEL HIT RN

FILE 'REGISTRY' ENTERED AT 17:36:05 ON 03 MAR 2008

L17 331 E1-331

L18 101 E332-432

L19 22 L17 AND (C22H25N3O OR C20H27F3N4 OR C21H22FN3 OR C24H29N3O OR C

L20 23 L18 AND (C21H22FN3 OR C20H22N4 OR C19H19N3 OR C23H26BRN3O4 OR C

L21 28 L19,L20

FILE 'HCAPLUS' ENTERED AT 18:14:52 ON 03 MAR 2008

L22 10 L21

L23 0 L22 AND L1

L24 10 L22 AND L14-16

FILE 'HCAOLD' ENTERED AT 18:15:25 ON 03 MAR 2008

L25 0 L10

L26 1 L11

SEL HIT RN

FILE 'REGISTRY' ENTERED AT 18:15:45 ON 03 MAR 2008

L27 1 E433

FILE 'HCAOLD' ENTERED AT 18:16:11 ON 03 MAR 2008

SEL AN L26

EDIT E434 /AN /OREF

FILE 'HCAPLUS' ENTERED AT 18:16:35 ON 03 MAR 2008

L28 2 E434

L29 12 L24,L28

=> => b reg

FILE 'REGISTRY' ENTERED AT 09:56:25 ON 04 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAR 2008 HIGHEST RN 1006431-93-1  
 DICTIONARY FILE UPDATES: 3 MAR 2008 HIGHEST RN 1006431-93-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnec/properties.html>

=> d que sta l9


L4 STR



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE  
 L5 ( 908950)SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES  
 L6 739 SEA FILE=REGISTRY SUB=L5 SSS FUL L4  
 L7 STR



NODE ATTRIBUTES:  
 CONNECT IS M3 RC AT 4  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE  
 L9 175 SEA FILE=REGISTRY SUB=L6 SSS FUL L7

100.0% PROCESSED 739 ITERATIONS  
 SEARCH TIME: 00.00.01

175 ANSWERS

=> b hcap  
FILE 'HCAPLUS' ENTERED AT 09:56:38 ON 04 MAR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Mar 2008 VOL 148 ISS 10  
FILE LAST UPDATED: 3 Mar 2008 (20080303/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr 114 tot


L14 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS ON SIN  
 AN 2004:321364 HCAPLUS  
 DN 140:321364  
 TI Preparation of substituted imidazoles, pyrazoles and amides as high  
 affinity C5a receptor modulators  
 IN Thurkauf, Andrew; He, Xiao-shu; Zhao, He; Peterson, John; Zhang, Xiaoyan;  
 Brodbeck, Robbin; Krause, James; Maynard, George; Hutchison, Alan  
 PA Neurogen Corporation, USA  
 SO U.S., 592 PP  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

| PATENT NO.            | KIND | DATE     | APPLICATION NO.  | DATE         |
|-----------------------|------|----------|------------------|--------------|
| US-----6723743        | B1   | 20040420 | 2000US-000672071 | 20000928 <-- |
| US-----6884815        | B1   | 20050426 | 2003US-000461311 | 20030612 <-- |
| US--2007027158        | A1   | 20070201 | 2004US-000853731 | 20040524     |
| US-----1271270        | B2   | 20070918 |                  |              |
| PRAI 1999US-00156390P | P    | 19990928 |                  |              |
| 2000US-00202749P      | P    | 20000508 |                  |              |
| 2000US-00212499P      | P    | 20000616 |                  |              |
| 2000US-00221787P      | P    | 20000731 |                  |              |
| 2000US-00224036P      | P    | 20000809 |                  |              |
| 2000US-00212449P      | P    | 20000616 |                  |              |
| 2000US-000672071      | A3   | 20000928 |                  |              |
| 2003US-000461311      | A3   | 20030612 |                  |              |
| OS MARPAT 140:321364  |      |          |                  |              |
| GI                    |      |          |                  |              |



AB The invention includes low mol. weight, non-peptidic, non-peptidomimetic, organic  
 mols. that can act as modulators of mammalian complement C5a receptors,  
 preferably ones that act as high affinity C5a receptor ligands and also  
 such ligands that can act as antagonists or inverse agonists of complement  
 C5a receptors. Preferred compds. of the invention possess some or all of  
 the following properties in that they are: (1) multi-aryl in structure;  
 (2) heteroaryl in structure; (3) a pharmaceutically acceptable oral dose  
 can provide a detectable in vivo effect; (4) comprise fewer than four or  
 preferably no amide bonds, and (5) capable of habiting leukocyte  
 chemotaxis at nanomolar or sub-nanomolar concns. Such compds. include  
 mainly substituted arylimidazoles I (m = 0-2; R1 = H, OH, halo, NH2, etc.;  
 R2 = alkyl, cycloalkyl, haloalkyl, etc.; R3, R32, R5, R6 = H, OH, halo,  
 NH2, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; R7 = 0-3 groups selected  
 from halo, NO2, CN, CF3, etc.-1, and also pyrazoles, amides, etc. Detailed  
 preparation of some of the title compds. was given. E.g., a multi-step  
 synthesis of I (Ar1 = Ph; R1, R31, R32, R7 = H; R2 = Bu; R4 =  
 3,4-methylenedioxyphenyl) was presented. The invention also includes  
 pharmaceutical composition comprising the title compds. and the use of such  
 compds. in treating a variety of disorders.  
 IT 439558-41-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (Preparation of substituted imidazoles, pyrazoles and amides as high


L14 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)  
 affinity C5a receptor modulators)  
 RN 439558-41-5 HCAPLUS  
 CN Isoquinoline, 2-[(1-butyl-2-phenyl-1H-imidazol-5-yl)methyl]-1-cyclopentyl-  
 1,2,3,4-tetrahydro- (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2008 ACS ON SIN  
 AN 2003:796668 HCAPLUS  
 DN 139:307760  
 TI Preparation of new aryl imidazoles and related compounds as C5a receptor  
 modulators  
 IN Luke, George P.; Maynard, George; Mitchell, Scott; Thurkauf, Andrew; Xie,  
 Linghong; Zhang, Luyun; Zhang, Suoning; Zhao, He; Chenard, Bertrand L.;  
 Gao, Yang; Han, Bingsong; He, Xiao Shu  
 PA Neurogen Corporation, USA  
 SO PCT Int. Appl., 356 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

| PATENT NO.                                                                                                                                                                                                                                                                                                                                                            | KIND | DATE     | APPLICATION NO.  | DATE         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|--------------|
| WO--2003082829                                                                                                                                                                                                                                                                                                                                                        | A1   | 20031009 | 2003WO-US0009938 | 20030328 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MY, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                  |              |
| RW: GH, GM, KE, LS, MW, MD, SD, SL, SS, TZ, UG, EM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG                                                                                                    |      |          |                  |              |
| CA-----5480888                                                                                                                                                                                                                                                                                                                                                        | A    | 20031009 | 2003CN-002480888 | 20030328 <-- |
| AU--2003228419                                                                                                                                                                                                                                                                                                                                                        | A1   | 20031013 | 2003AU-000228419 | 20030328 <-- |
| US--2004116424                                                                                                                                                                                                                                                                                                                                                        | A1   | 20040617 | 2003US-000405989 | 20030328 <-- |
| US-----1186734                                                                                                                                                                                                                                                                                                                                                        | B2   | 20070306 |                  |              |
| EP-----1490343                                                                                                                                                                                                                                                                                                                                                        | A1   | 20041229 | 2003EP-000726169 | 20030328 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK                                                                                                                                                                                                                                         |      |          |                  |              |
| CN-----1646497                                                                                                                                                                                                                                                                                                                                                        | A    | 20050727 | 2003CN-000807529 | 20030328 <-- |
| JP--2005528368                                                                                                                                                                                                                                                                                                                                                        | T    | 20050922 | 2003JP-000580297 | 20030328 <-- |
| BR--200308721                                                                                                                                                                                                                                                                                                                                                         | A    | 20070109 | 2003BR-00008721  | 20030328 <-- |
| MX-20040909419                                                                                                                                                                                                                                                                                                                                                        | A    | 20050125 | 2004MX-PA0009419 | 20040928     |
| US--2007208048                                                                                                                                                                                                                                                                                                                                                        | A1   | 20070906 | 2007US-000680865 | 20070301     |
| PRAI 2002US-00369112P                                                                                                                                                                                                                                                                                                                                                 | P    | 20020329 |                  |              |
| 2002US-00392145P                                                                                                                                                                                                                                                                                                                                                      | P    | 20020626 |                  |              |
| 2003US-000405989                                                                                                                                                                                                                                                                                                                                                      | A3   | 20030328 |                  |              |
| 2003WO-US0009938                                                                                                                                                                                                                                                                                                                                                      | W    | 20030328 |                  |              |
| OS MARPAT 139:307760                                                                                                                                                                                                                                                                                                                                                  |      |          |                  |              |
| GI                                                                                                                                                                                                                                                                                                                                                                    |      |          |                  |              |




AB The title imidazoles, pyrazoles, pyridazines (I; the ring system in the  
 formula I = 5-membered heteroaryl ring system (in which x = 0, A = C, N,  
 O, S, and E and G = C, N, provided that the 5-membered heteroaryl ring  
 system does not contain more than 3 heteroatoms or more than 1 O or S  
 atom) or 6-membered heteroaryl ring system (in which x = 1, A, B, E, and G  
 = C, N, and provided that the 6-membered heteroaryl ring system does not  
 contain more than 3 N atoms); R, R1 = H, OH, halo, etc.; when E = N, then  
 R2 = alkyl, alkenyl, CH2Ph, etc.; when E = C, then R2 = H, halo, OH, etc.;  
 R3 = H, alkyl, alkenyl, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; R5,  
 R6 = H, alkyl; z = 1-3; Ar1 = (un)substituted aryl, heteroaryl, Ph fused

L14 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)  
 to 5-7 membered (un)satd. ring that has 0-2 ring atoms chosen from N, O,  
 and S; Ar2 = cycloalkyl, cycloalkylalkyl, aryl having 1 ring or 2 fused or  
 pendant rings, etc.; y = 1-4) which are ligands of C5a receptors, were  
 prep'd. and formulated. E.g., a multi-step synthesis of II (starting from  
 Me benzimidate hydrochloride and 1-butylamine), was given. Preferred  
 compds. I bind to C5a receptors with high affinity (biol. data given) and  
 exhibit neutral antagonist or inverse agonist activity at C5a receptors.  
 This invention also relates to pharmaceutical compds. comprising such  
 compds. It further relates to the use of such compds. in treating a  
 variety of inflammatory and immune system disorders.  
 IT 610289-03-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (Preparation of new aryl imidazoles and related compds. as C5a receptor  
 modulators)  
 RN 610289-03-7 HCAPLUS  
 CN Isoquinoline, 2-[(1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-  
 yl)methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)





RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L14 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:79667 HCAPLUS  
 DN 139:307693  
 TI Preparation of substituted tetrahydroisoquinolines as C5a receptor  
 modulators  
 IN Mitchell, Scott; Ohliger, Robert; Zhang, Luyan; Zhao, He; Currie, Kevin;  
 Lee, Kyungae  
 PA Neurogen Corporation, USA  
 SO PCT Int. Appl., 104 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


| PATENT NO.            | KIND                                                                                                                                                                                                                                                                                                                                                                   | DATE     | APPLICATION NO.  | DATE         |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|------------------|--------------|
| WO--2003082828        | A1                                                                                                                                                                                                                                                                                                                                                                     | 20031009 | 2003WO-US0009046 | 20030325 <-- |
| W:                    | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TE, UA, UG, US, VE, VC, VN, YU, ZA, ZM, ZW |          |                  |              |
| RW:                   | GH, GM, KE, LS, MW, ME, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG                                                                                                         |          |                  |              |
| CA-----2479930        | A1                                                                                                                                                                                                                                                                                                                                                                     | 20031009 | 2003CA-002479930 | 20030325 <-- |
| AU--2003218374        | A1                                                                                                                                                                                                                                                                                                                                                                     | 20031013 | 2003AU-000218374 | 20030325 <-- |
| EP-----1407798        | A1                                                                                                                                                                                                                                                                                                                                                                     | 20041222 | 2003EP-000714371 | 20030325 <-- |
| R:                    | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK                                                                                                                                                                                                                                             |          |                  |              |
| JP--2006508894        | T                                                                                                                                                                                                                                                                                                                                                                      | 20060316 | 2003JP-000580296 | 20030325 <-- |
| US--2004006068        | A1                                                                                                                                                                                                                                                                                                                                                                     | 20040108 | 2003US-000401135 | 20030327 <-- |
| US-----6777422        | B2                                                                                                                                                                                                                                                                                                                                                                     | 20040817 |                  |              |
| US--2004204446        | A1                                                                                                                                                                                                                                                                                                                                                                     | 20041014 | 2004US-000824826 | 20040415     |
| US-----4916830        | B2                                                                                                                                                                                                                                                                                                                                                                     | 20050712 |                  |              |
| PPAI 2002US-00368199P | P                                                                                                                                                                                                                                                                                                                                                                      | 20020328 |                  |              |
| 2003WO-US0009046      | W                                                                                                                                                                                                                                                                                                                                                                      | 20030325 |                  |              |
| 2003US-000401135      | A1                                                                                                                                                                                                                                                                                                                                                                     | 20030327 |                  |              |
| OS MARPAT 139:307693  |                                                                                                                                                                                                                                                                                                                                                                        |          |                  |              |
| GI                    |                                                                                                                                                                                                                                                                                                                                                                        |          |                  |              |



II

L14 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:356252 HCAPLUS  
 DN 139:368891  
 TI Preparation of arylazolecarboxamides for the treatment of obesity  
 IN Colish, Philip D. G.; O'Connor, Stephen J.; Wickens, Philip; Zhang, Chengzhi; Zhang, Hai-Jun  
 PA Bayer Corporation, USA  
 SO PCT Int. Appl., 253 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

| PATENT NO.            | KIND                                                                                                                                                                                                                                                                                                                                                               | DATE     | APPLICATION NO.   | DATE         |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-------------------|--------------|
| WO--2003037332        | A1                                                                                                                                                                                                                                                                                                                                                                 | 20030508 | 2002WO-US00032895 | 20021015 <-- |
| W:                    | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DS, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TE, UA, UG, US, VE, VC, VN, YU, ZA, ZM, ZW |          |                   |              |
| RW:                   | GH, GM, KE, LS, MW, ME, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG                                                                                                                 |          |                   |              |
| CA-----2463441        | A1                                                                                                                                                                                                                                                                                                                                                                 | 20030508 | 2002CA-002463441  | 20021015 <-- |
| AU--2002348440        | A1                                                                                                                                                                                                                                                                                                                                                                 | 20030512 | 2002AU-000348440  | 20021015 <-- |
| EP-----1435951        | A1                                                                                                                                                                                                                                                                                                                                                                 | 20040714 | 2002EP-000782159  | 20021015 <-- |
| EP-----1435951        | B1                                                                                                                                                                                                                                                                                                                                                                 | 20060118 |                   |              |
| R:                    | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK                                                                                                                                                                                                                                             |          |                   |              |
| JP--2005507932        | T                                                                                                                                                                                                                                                                                                                                                                  | 20050324 | 2003JP-000539676  | 20021015 <-- |
| ES-----2256560        | T3                                                                                                                                                                                                                                                                                                                                                                 | 20060716 | 2002ES-000782159  | 20021015 <-- |
| US--2005014805        | A1                                                                                                                                                                                                                                                                                                                                                                 | 20050120 | 2004US-000490826  | 20040326     |
| MX--2004PA02931       | A                                                                                                                                                                                                                                                                                                                                                                  | 20050411 | 2004MX-PA0002931  | 20040329     |
| PPAI 2001US-00329236P | P                                                                                                                                                                                                                                                                                                                                                                  | 20011012 |                   |              |
| 2002WO-US0032895      | W                                                                                                                                                                                                                                                                                                                                                                  | 20021015 |                   |              |
| OS MARPAT 138:368891  |                                                                                                                                                                                                                                                                                                                                                                    |          |                   |              |
| GI                    |                                                                                                                                                                                                                                                                                                                                                                    |          |                   |              |



I

AB Title compds. [I; R1 = ZCR11R12CO2R13; Z = O, S; R11-R15 = H, alkyl; R2, R3 = H, Me; R1R2 = CH2CH2CH(CHR15CO2R14); Y = NR4, O, S; R4 = H, alkyl, alkoxyalkyl, arylalkoxyalkyl; R5 = H, alkyl, Ph, halophenyl, alkylphenyl, alkoxyphenyl; R6 = COMe; R61 = OH, alkoxy, benzyloxy, amino, etc.], were prepared for treatment of obesity and complications (no data). Thus, tert-Bu 2-methyl-2-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]thio]propionate (preparation given), [1,1'-bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH2Cl2, and aqueous NaHCO3 were heated at 85° in PhMe for 48 h to give 98% coupling product. The latter was sequentially saponified with aqueous KOH in EtOH, amidated with COCl2/2,4-dimethylaniline, hydrolyzed with CF3CO2H in CH2Cl2, and saltified with NaOH in H2O/MeCN to give Na 2-[[4-[[4-[(2,4-dimethylphenyl)amino]carbonyl]-1-pentyl-1H-imidazol-2-yl]phenyl]thio]-2-methylpropionate.


IT 521084-04-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of arylazolecarboxamides for the treatment of obesity)

RN 521084-04-8 HCAPLUS  
 CN Propanoic acid, 2-[[4-[1-(2-methoxyethyl)-4-methyl-5-(1-

L14 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 AB The title compds. [I; X = 1-3; R = halo, OH, alkoxy, etc.; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2-R4 = H, halo, alkyl, alkoxy; R5, R6 = H, halo, OH, etc.; R7 = H, alkyl, alkenyl, etc.; Ar1 = (un)substituted Ph, naphthyl, biphenyl, etc.; Ar2 = (un)substituted aryl, heteroaryl] which are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathol. C5a receptor activation in humans, domesticated companion animals and livestock animals, were prepared. Thus, reacting 6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline.HCl with N-(1-fluorobenzyl)-N-(indan-2-yl)-2-bromoacetamide in the presence of K2CO3 in MeCN afforded II. Preferred compds. I exhibit IC50 values of less than 1 µM in the assay for C5a receptor mediated chemotaxis. Pharmaceutical compds. and methods for using them to treat disorders associated with pathol. C5a receptor activation are provided, as are methods for using such ligands for receptor localisation studies.


IT 610289-03-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of new aryl imidazoles and related compds. as C5a receptor modulators)

RN 610289-03-7 HCAPLUS  
 CN Isoquinoline, 2-[[1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-yl]methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 piperidinylcarbonyl)-1H-imidazol-2-yl]phenyl]thio]-2-methyl- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L14 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2008 ACS ON SIN  
AN 2003:58008 HCAPLUS  
DN 138:106702

TI Preparation of 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands  
IN Thürkaut, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.  
PA Neurogen Corporation, USA  
SO U.S. Pat. Appl. Publ., 37 pp., Cont. of U.S. Ser. No. 281,169.  
CODEN: USXXCO

DT Patent  
LA English  
FAN.CMI 1

| PATENT NO.            | KIND | DATE     | APPLICATION NO.  | DATE         |
|-----------------------|------|----------|------------------|--------------|
| PI US--2003018025     | A1   | 20030123 | 2002US-000156262 | 20020528 <-- |
| PRAI 1995US-000478291 | B1   | 19950607 |                  |              |
| GI 1999US-000281169   | A1   | 19990330 |                  |              |


OS MARPAT 138:106702



AB The imidazoles I (R1 = optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl; naphthyl; X, Z, and Y = optionally substituted nitrogen or carbon atoms; R2 = H, alkyl; n = 0, 1 or 2; and R3 and R4 = H, alkyl, R3R4N may form a ring) and the pharmaceutically acceptable addition salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrgs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Thus, 2-phenyl-4-(hydroxymethyl)imidazole was treated with SOCl2 followed by 1-(2-methoxyphenyl)piperazine to give 2-phenyl-4-(5)-[4-(2-methoxyphenyl)piperazin-1-yl)methyl]imidazole. 2-Phenyl-4-(5)-[4-(2-pyrimidinyl)piperazin-1-yl)methyl]imidazole dihydrochloride was shown to bind to the dopamine D4 receptor site (K1 = 1033, 8200, 2.7 for D2, D3, D4 binding sites, resp.).

TI 179332-44-6P  
RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of imidazole derivs. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)

RN 179332-44-6 HCAPLUS  
CN Piperidine, 1-[(1-methyl-2-phenyl-1H-imidazol-5-yl)methyl]-4-(phenylmethyl)- (CA INDEX NAME)




L14 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)

AB Title compds. I (R1 = H, alkyl, cycloalkyl, allyl, aryl, heterocyclyl; R2-3 = H, alkyl, cycloalkyl, allyl, aryl, heterocyclyl; X = S, O; A = imidazolyl) were prepared. For instance, N-tert-butoxycarbonyl-4-piperidone was used to alkylate aniline (CH2Cl2, HOAc, NaBH(OAc)3), the product converted to the corresponding carbanoyl chloride (CH2Cl2/PhMe, NaHCO3, Cl2CO) which was reacted with methylaniline to give the urea intermediate. This was deprotected and the resulting piperidine alkylated with 5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazole-4-carboxaldehyde (CH2Cl2, NaBH(OAc)3) to afford II. In the gp120-SCD4-CRS binding assay, compds. of the invention had IC50 of about 0.5 to about 1500 nM. Compds. I prevent the human immunodeficiency virus (HIV) from entering cells by blocking interaction of the viral envelope protein gp120 with a chemokine receptor on the cell surface. I are useful for the treatment of diseases mediated by the human immunodeficiency virus (HIV), either alone or in combination with other inhibitors of HIV viral replication or with pharmacoenhancers.

TI 466663-31-OP, 1-Benzyl-1-[1-[(3-benzyl-5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl)methyl]-4-piperidinyl]-3-methylurea  
RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(HIV inhibitor; preparation of imidazolylalkyl-aminopiperidines as HIV inhibitors)

RN 466663-31-0 HCAPLUS  
CN Uses, N-methyl-N-[1-[(4-methyl-1-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-5-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (CA INDEX NAME)





L14 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS ON SIN  
AN 2002:77952 HCAPLUS  
DN 137:279193

TI Preparation of imidazolylalkyl-aminopiperidines as HIV inhibitors  
IN Edlin, Christopher David; Redshaw, Sally; Smith, Ian Edward David; Walter, Daryl Simon  
PA F. Hoffmann-La Roche A.-G., Switz.  
SO PCT Int. Appl., 179 pp.  
CODEN: PIXX32

DT Patent  
LA English  
FAN.CMI 1

| PATENT NO.                                                                                                                                                                                                                                                                                                                            | KIND | DATE     | APPLICATION NO.  | DATE         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|--------------|
| PI WO--2002079186                                                                                                                                                                                                                                                                                                                     | A2   | 20021010 | 2002WO-EP0003193 | 20020321 <-- |
| WO--2002079186                                                                                                                                                                                                                                                                                                                        | A3   | 20030501 |                  |              |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW |      |          |                  |              |
| PM: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, CO, GW, ML, MR, NE, SN, TD, TG                                                                                                    |      |          |                  |              |
| CA-----2441778                                                                                                                                                                                                                                                                                                                        | A1   | 20021010 | 2002CA-002441778 | 20020321 <-- |
| AU--2002304773                                                                                                                                                                                                                                                                                                                        | A1   | 20021015 | 2002AU-00304773  | 20020321 <-- |
| BR--2002000572                                                                                                                                                                                                                                                                                                                        | A    | 20040330 | 2002BR-00000572  | 20020321 <-- |
| EP-----1417202                                                                                                                                                                                                                                                                                                                        | A2   | 20040512 | 2002EP-000732512 | 20020321 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR                                                                                                                                                                                                                             |      |          |                  |              |
| CN-----1500086                                                                                                                                                                                                                                                                                                                        | T    | 20040526 | 2002CN-000807803 | 20020321 <-- |
| JP--2004528318                                                                                                                                                                                                                                                                                                                        | T    | 20040916 | 2002JP-000577812 | 20020321 <-- |
| US--2003069276                                                                                                                                                                                                                                                                                                                        | A1   | 20030410 | 2002US-000104117 | 20020322 <-- |
| ZA--200306890                                                                                                                                                                                                                                                                                                                         | A    | 20041103 | 2003ZA-00006890  | 20030903     |
| MX--2003PA08931                                                                                                                                                                                                                                                                                                                       | A    | 20050307 | 2003MX-PA0008931 | 20030930     |
| PRAI 2001GB-000008099                                                                                                                                                                                                                                                                                                                 | A    | 20010330 |                  |              |
| OS 2002WO-EP0003193                                                                                                                                                                                                                                                                                                                   | W    | 20020321 |                  |              |

GI MARPAT 137:279193





L14 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS ON SIN  
AN 2002:487497 HCAPLUS  
DN 137:78952

TI Preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators  
IN Thürkaut, Andrew; Zhang, Xiaoyan; He, Xia-Shu; Zhao, He; Peterson, John; Maynard, George; Ohliger, Robert  
PA Neurogen Corporation, USA  
SO PCT Int. Appl., 609 pp.  
CODEN: PIXX32

DT Patent  
LA English  
FAN.CMI 1


| PATENT NO.                                                                                                                                                                                                                                                                                                                            | KIND | DATE     | APPLICATION NO.  | DATE         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------|------------------|--------------|
| PI WO--2002049993                                                                                                                                                                                                                                                                                                                     | A2   | 20020627 | 2000WO-US0026816 | 20000929 <-- |
| WO--2002049993                                                                                                                                                                                                                                                                                                                        | A3   | 20030220 |                  |              |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, EE, FI, GB, GD, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KS, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW |      |          |                  |              |
| PM: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GM, ML, MR, NE, SN, TD, TG                                                                                                                                                |      |          |                  |              |
| CA-----2420215                                                                                                                                                                                                                                                                                                                        | A1   | 20020627 | 2000CA-002420215 | 20000929 <-- |
| AU--2000076225                                                                                                                                                                                                                                                                                                                        | A    | 20020701 | 2000AU-00076225  | 20000929 <-- |
| EP--2000076225                                                                                                                                                                                                                                                                                                                        | A    | 20030702 | 2000EP-00076225  | 20000929 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL                                                                                                                                                                                                                                 |      |          |                  |              |
| ZA--2003001160                                                                                                                                                                                                                                                                                                                        | A    | 20040212 | 2003ZA-000001160 | 20000929 <-- |
| BR--2000017338                                                                                                                                                                                                                                                                                                                        | A    | 20040427 | 2000BR-000017338 | 20000929 <-- |
| JP--2004525873                                                                                                                                                                                                                                                                                                                        | T    | 20040826 | 2002JP-00051496  | 20000929 <-- |
| NO--2003001370                                                                                                                                                                                                                                                                                                                        | A    | 20030530 | 2003NO-00001370  | 20030326 <-- |
| MX--2003PA02788                                                                                                                                                                                                                                                                                                                       | A    | 20041213 | 2003MX-PA0002788 | 20030328 <-- |
| PRAI 2000US-00227454P                                                                                                                                                                                                                                                                                                                 | P    | 20000823 |                  |              |
| OS 2000WO-US0026816                                                                                                                                                                                                                                                                                                                   | W    | 20000929 |                  |              |

GI MARPAT 137:78952




AB The invention includes low mol. weight, non-peptidic, non-peptidomimetic, organic acids, that can act as modulators of mammalian complement C5a receptors, and preferably ones that act as high affinity C5a receptor ligands and also such ligands that can act as antagonists or inverse agonists of complement C5a receptors. Preferred compds. of the invention possess some or all of the following properties in that they are: (1) multi-aryl in structure; (2) heteroaryl in structure; (3) a pharmaceutically acceptable oral dose can provide a detectable in vivo effect; (4) comprise fewer than four or preferably no amide bonds; and (5) capable of having leukocyte chemotaxis at nanomolar or sub-nanomolar concns. Such compds. include imidazoles I (R1 = H, OH, halo, etc.; R2 = alkyl, cycloalkyl, etc.; R3 H, alkyl, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl, etc.), pyrazoles II (R = H, OH, halo, etc.; R2, R3 = H, OH, halo, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl, etc.), etc. Detailed preparation of some compds. I-III was given. E.g., a multi-step synthesis of I (Ar1 = Ph, R1, R3 = H; R2 = Bu, R4 = 3,4-methylenedioxyphenyl) was presented. The invention also includes pharmaceutical composition comprising such compds. I-III and the use of such compds. in treating a variety of inflammatory and immune system disorders.

L14 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 IT 439558-41-SP  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators)  
 RN 439558-41-5 HCAPLUS  
 CN Isoquinoline, 2-[(1-butyl-2-phenyl-1H-imidazol-5-yl)methyl]-1-cyclopentyl-1,2,3,4-tetrahydro- (CA INDEX NAME)




L14 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1996-467020 HCAPLUS  
 DN 125:114630  
 TI Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands  
 IN Thurkauf, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.  
 PA Neuron Corporation, USA  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 5  
 PATENT NO. KIND DATE APPLICATION NO. DATE  
 PI WO-----9616040 A1 19960530 1995WO-US0015262 19951122 <--  
 W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NE, NL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT  
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG  
 US-----5681956 A 19971028 1995US-000401201 19950309 <--  
 US-----5633377 A 19970527 1995US-000462833 19950605 <--  
 US-----5646281 A 19970708 1995US-000461125 19950605 <--  
 US-----5656762 A 19970812 1995US-000461858 19950605 <--  
 US-----5712392 A 19980127 1995US-000464548 19950605 <--  
 AU-----9643689 A 19960617 1996AU-000043689 19951122 <--  
 ZA-----9509910 A 19970822 1995ZA-000009910 19951122 <--  
 ZA-----9509911 A 19970822 1995ZA-000009911 19951122 <--  
 EP-----793653 A1 19970910 1995EP-000942473 19951122 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
 ZA-----9707500 A 19980223 1997ZA-000007500 19951122 <--  
 JP-----10502670 T 19980310 1995JP-000517074 19951122 <--  
 JP-----2941950 B2 19980830  
 BR-----9509760 A 19980630 1995BR-000009760 19951122 <--  
 US-----6069251 A 20000530 1997US-000859861 19970521 <--  
 US-----6358955 B1 20020319 2000US-000497988 20000204 <--  
 US-----2002143044 A1 20021003 2002US-000100693 20020318 <--  
 US-----6797824 B2 20040928  
 PRAI 1994US-000344154 A2 19941123  
 1994US-000344552 A2 19941123  
 1995US-000401201 A2 19950309  
 1995US-000635256 A2 19951228  
 1995US-00081317 A2 19951108  
 1994US-000313435 A2 19940927  
 1995US-000462833 A1 19950605  
 1995MO-US0015262 W 19951122  
 1997US-000859861 A1 19970521  
 2000US-000497988 A1 20000204  
 OS MARPAT 125:114630  
 GI




AB Disclosed are compds. (I), wherein R1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R3 and R4 are organic or inorg. substituents which may together form ring structures; m is zero, one or two; and R5 and R6 are organic or inorg. substituents; and the pharmaceutically acceptable addition salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment


L14 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Specifically, 2-phenyl-4-(5)-[(4-(2-pyrimidinyl)piperazin-1-yl)methyl]imidazole dihydrochloride was prepd. and was shown to bind to the dopamine D4 receptor site (K1 = 1033, 8200, 2.7 for D2, D3, D4 binding sites, resp.).  
 IT 179332-44-6P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazole derivs. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)  
 RN 179332-44-6 HCAPLUS  
 CN Piperidine, 1-[(1-methyl-2-phenyl-1H-imidazol-5-yl)methyl]-4-(phenylmethyl)- (CA INDEX NAME)




L14 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1983:612453 HCAPLUS  
 DN 99:212453  
 OREF 99:32695a,32698a  
 TI Reactions of 4-imidazolidinone and 4-imidazolinone derivatives  
 AU Abd El-Gawad, Ibrahim I.; Harhash, Abd El-Hamid; Abou-Elzahab, Mohamed M.  
 CS Fac. Sci., Mansoura Univ., Mansoura, Egypt  
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1983), 22B(5), 481-3  
 CODEN: IJSBDB; ISSN: 0376-4699  
 DT Journal  
 LA English  
 OS CASREACT 99:212453  
 GI



AB Mannich reaction of imidazolidinones I (R = Ph, 3-MeC6H4, 4-MeC6H4) with piperidine and morpholine gave the N-Mannich bases whereas imidazolinones II gave the C-Mannich bases. Reaction of II with PhMgBr or MeMgI gave imidazolidinones III (R1 = Ph, Me). Treating I with Me2SO4, acrylonitrile, or Ac2O gave the N-alkylation or N-acylation products.  
 IT 87751-51-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, with thiocresol)  
 RN 87751-51-7 HCAPLUS  
 CN 4H-Imidazol-4-one, 1,5-dihydro-1-(3-methylphenyl)-2,5-diphenyl-5-(1-piperidinylmethyl)- (CA INDEX NAME)




IT 87751-53-9P 87751-55-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 87751-53-9 HCAPLUS  
 CN 4H-Imidazol-4-one, 1,5-dihydro-1-(3-methylphenyl)-2,5-diphenyl-5-(1-piperidinylmethyl)- (CA INDEX NAME)



RN 87751-55-1 HCAPLUS  
 CN 4H-Imidazol-4-one, 1,5-dihydro-1-(4-methylphenyl)-2,5-diphenyl-5-(1-piperidinylmethyl)- (CA INDEX NAME)


L14 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



=> d bib abs hitrn fhitstr l15 tot

L15 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN  
 AN 2007:113504 HCAPLUS  
 DN 146:206222  
 TI Preparation of spiro-cyclic compounds as acetyl-CoA carboxylase inhibitors  
 IN Kamata, Makoto; Fukatsu, Kohji; Yamashita, Tohru; Furuyama, Naoki; Endo, Satoshi  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 450pp.  
 CODEN: PIXX32  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

| PATENT NO.            | KIND                                                                                                                                                                                                                                                                                                                                                                                                                       | DATE     | APPLICATION NO.  | DATE     |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|------------------|----------|
| WO-2007013691         | A1                                                                                                                                                                                                                                                                                                                                                                                                                         | 20070201 | 2006WO-JP0315447 | 20060728 |
| W:                    | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |          |                  |          |
| RW:                   | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM                                                                                                                                 |          |                  |          |
| PRAI 2005JP-000221959 | A                                                                                                                                                                                                                                                                                                                                                                                                                          | 20050729 |                  |          |
| 2006JP-000159117      | A                                                                                                                                                                                                                                                                                                                                                                                                                          | 20060607 |                  |          |
| OS MAPPAT 146:206222  |                                                                                                                                                                                                                                                                                                                                                                                                                            |          |                  |          |
| GI                    |                                                                                                                                                                                                                                                                                                                                                                                                                            |          |                  |          |



AB The title comps. I [E represents a cyclic group which may be substituted; D represents carbonyl or sulfonyl; A represents CH or N; the ring P represents a 5- to 7-membered ring which may be further substituted; the ring Q represents a 5- to 7-membered non-aromatic ring which may be further substituted; and the ring R represents a 5- to 7-membered non-aromatic ring which may be further substituted and which may be fused] are prepared I are useful for the prevention/treatment of obesity, diabetes, etc. Thus, 7-[1-(9-anthrylcarbonyl)piperidin-4-yl]-2-ethyl-2,7-diazaspiro[4.5]decan-1-one was prepared in a multistep process from piperidine-1,3-dicarboxylic acid 3-Bt 1-tert-Bu ester and bromoacetonitrile. Several comps. of this invention showed IC50 values  $\leq 10$  nM against acetyl-CoA carboxylase 2. Formulations are given.

IT 923007-47-OP 923007-48-IP  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of spiro-cyclic comps. as acetyl-CoA carboxylase inhibitors)



IT 923004-94-SP: 7-[1-[(4-Amino-1-benzyl-2-phenyl-1H-imidazol-5-yl)carbonyl]piperidin-4-yl]-3,3-dimethyl-2-oxa-7-azaspiro[4.5]decan-1-one  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of spiro-cyclic comps. as acetyl-CoA carboxylase inhibitors)

IT 923007-47-OP  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of spiro-cyclic comps. as acetyl-CoA carboxylase inhibitors)

RN 923007-47-0 HCAPLUS


L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN  
 AN 2006:845146 HCAPLUS  
 DN 145:271760  
 TI Preparation of thiazole amides, imidazole amides and related analogues as histamine H3 receptor modulators  
 IN Pringle, Wallace C.; Peterson, John M.; Xie, Linghong; Ge, Ping; Gao, Yang; Ochterski, Joseph W.; Lan, Jiong  
 PA Neurogen Corporation, USA  
 SO PCT Int. Appl., 329pp.  
 CODEN: PIXX32  
 DT Patent  
 LA English  
 FAN.CNT 1

| PATENT NO.           | KIND                                                                                                                                                                                                                                                                                                                                                                                                                   | DATE     | APPLICATION NO.  | DATE     |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|------------------|----------|
| WO-2006089076        | A2                                                                                                                                                                                                                                                                                                                                                                                                                     | 20060824 | 2006WO-US0005562 | 20060216 |
| WO-2006089076        | A3                                                                                                                                                                                                                                                                                                                                                                                                                     | 20061221 |                  |          |
| WO-2006089076        | A9                                                                                                                                                                                                                                                                                                                                                                                                                     | 20070426 |                  |          |
| W:                   | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                  |          |
| RW:                  | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA                                                                                                                 |          |                  |          |
| EP-----184848        | A2                                                                                                                                                                                                                                                                                                                                                                                                                     | 20071021 | 2006EP-000735288 | 20060216 |
| R:                   | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, BR, MK, TU                                                                                                                                                                                                                                                                         |          |                  |          |
| PRAI 2005US-0064558P | P                                                                                                                                                                                                                                                                                                                                                                                                                      | 20050218 |                  |          |
| 2005US-00720500P     | P                                                                                                                                                                                                                                                                                                                                                                                                                      | 20050926 |                  |          |
| 2006WO-US0005562     | W                                                                                                                                                                                                                                                                                                                                                                                                                      | 20060216 |                  |          |
| OS MAPPAT 145:271760 |                                                                                                                                                                                                                                                                                                                                                                                                                        |          |                  |          |
| GI                   |                                                                                                                                                                                                                                                                                                                                                                                                                        |          |                  |          |



AB The title comps. I [R1 = (un)substituted alkyl, alkenyl or cycloalkylalkyl; or R1 taken together with R2 or R4 can form (un)substituted 4-8 membered heterocycloalkyl; R2 = alkyl, alkenyl, cycloalkylalkyl; or R2 taken together with R1, R3 or R4 can form (un)substituted 4-8 membered heterocycloalkyl; R3 = H, alkyl, alkenyl, cycloalkylalkyl; or R3 taken together with R2 or R4 can form (un)substituted 4-8 membered heterocycloalkyl; R4 = H or taken together with R1, R2 or R3 can form (un)substituted 4-8 membered heterocycloalkyl; n = 1-3; X = CH2 or C(O); Y = thiazole, imidazole, etc.; Ar = (un)substituted Ph, naphthyl, biphenyl, 5-13 membered heteroaryl; with proviso] which may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals, were prepared Thus, reacting 2-bromo-4-methylthiazole-5-carboxylic acid with

L15 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)  
 CN Carbamic acid, N-[5-[(4-(3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]dec-7-yl)-1-piperidinyl)carbonyl]-2-phenyl-1-(phenylmethyl)-1H-imidazol-4-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)  
 N-isopropylpiperazine afforded II. Over 1000 comps. I were prepd. Most of them exhibit a KI in the chimeric human H3 receptor GTP binding assay that is less than 1  $\mu$ M. Comps. I may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical comps. and methods for treating the mentioned above disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

IT 906476-90-2P 906476-91-3P 906476-92-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazole amides, imidazole amides and related analogs as histamine H3 receptor modulators)

IT 906476-90-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazole amides, imidazole amides and related analogs as histamine H3 receptor modulators)

RN 906476-90-2 HCAPLUS

CN 4-Piperidinamine, N,N-diethyl-1-[(1-ethyl-4-methyl-2-(1-naphthalenyl)-1H-imidazol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 09:58:24 ON 04 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 09:58:24 ON 04 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


FILE 'USPAT2' ENTERED AT 09:58:24 ON 04 MAR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr 120 tot
```


L20 ANSWER 1 OF 14 USPATFULL on STN  
 AN 2007:30883 USPATFULL  
 TI New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators  
 IN Luke, George P., Clinton, CT, UNITED STATES  
 Maynard, George D., Clinton, CT, UNITED STATES  
 Mitchell, Scott, East Haven, CT, UNITED STATES  
 Thurkauf, Andrew, Danbury, CT, UNITED STATES  
 Xie, Linghong, Guilford, CT, UNITED STATES  
 Zhang, LuZan, Branford, CT, UNITED STATES  
 Zhang, Suoning, Branford, CT, UNITED STATES  
 Zhao, He, Branford, CT, UNITED STATES  
 Chenard, Bertrand L., Waterford, CT, UNITED STATES  
 Gao, Yang, Branford, CT, UNITED STATES  
 Han, Bingsong, Hamden, CT, UNITED STATES  
 He, Xiao Shu, Branford, CT, UNITED STATES  
 US-20070208048 A1 20070806  
 PI 2007US-000680865 A1 20070301 (11)  
 RLI Division of Ser. No. 2003US-000405989, filed on 28 Mar 2003, GRANTED,  
 Pat. No. US-----7186734  
 PRAI 2002US-000369112P 20020329 (60)  
 2002US-000392145P 20020626 (60)  
 DT Utility  
 FS APPLICATION  
 LREP NEUROGEN CORPORATION, 35 NORTHEAST INDUSTRIAL ROAD, BRANFORD, CT, 06405,  
 US  
 CLMN Number of Claims: 22  
 ECL Exemplary Claim: 1-84  
 DRWN No Drawings  
 LN.CNT 4832  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention provides Aryl substituted imidazoles, pyrazoles,  
 pyridines and related compounds of the Formula ##STR1## where the  
 ring system represented by ##STR2## is a 5 membered heteroaryl ring  
 system, in which x is 0, A is chosen from carbon and heteroatoms  
 nitrogen, oxygen, and sulfur, and E and G are independently carbon or  
 nitrogen provided that the 5 membered heteroaryl ring system does not  
 contain more than 3 heteroatoms or more than 1 oxygen or sulfur atom, or  
 a 6 membered heteroaryl ring system, in which x is 1, A, B, E, and G are  
 independently chosen from carbon and nitrogen, provided that the 6  
 membered heteroaryl ring system does not contain more than 3 nitrogen  
 atoms. The remaining variables, Ar.sub.1, Ar.sub.2, R, R.sub.1, R.sub.2,  
 R.sub.3, R.sub.4, R.sub.5, R.sub.6, y and z are defined herein. Such  
 compounds are ligands of C5a receptors. Preferred compounds of the  
 invention act bind to C5a receptors with high affinity and exhibit  
 neutral antagonist or inverse agonist activity at C5a receptors. This  
 invention also relates to pharmaceutical compositions comprising such  
 compounds. It further relates to the use of such compounds in treating a  
 variety of inflammatory and immune system disorders.  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 610289-03-7P  
 (preparation of new aryl imidazoles and related compds. as C5a receptor  
 modulators)  
 RN 610289-03-7 USPATFULL  
 CN Isoquinoline, 2-([1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-  
 yl)methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)



L20 ANSWER 2 OF 14 USPATFULL on STN  
 AN 2007:30883 USPATFULL  
 TI High affinity small molecule C5a receptor modulators  
 IN Thurkauf, Andrew, Danbury, CT, UNITED STATES  
 He, Xiao-shu, Branford, CT, UNITED STATES  
 Zhao, He, Branford, CT, UNITED STATES  
 PA Neurogen Corporation (U.S. corporation)  
 PI US-20070027158 A1 20070201  
 US-----7271270 B2 20070918  
 2004US-000853731 A1 20040524 (10)  
 RLI Division of Ser. No. 2003US-000461311, filed on 12 Jun 2003, PENDING  
 Division of Ser. No. 2000US-000672071, filed on 28 Sep 2000, GRANTED,  
 Pat. No. US-----6723743  
 PRAI 1998US-000156390P 19990928 (60)  
 2000US-000202749P 20000508 (60)  
 2000US-000212449P 20000616 (60)  
 2000US-000221787P 20000731 (60)  
 2000US-000224036P 20000809 (60)  
 DT Utility  
 FS APPLICATION  
 LREP Edwards & Angell, LLP, Intellectual Property Practice Group, P.O. Box  
 55874, Boston, MA, 02205, US  
 CLMN Number of Claims: 37  
 ECL Exemplary Claim: 1-26  
 DRWN 1 Drawing Page(s)  
 LN.CNT 5702  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention relates to low molecular weight, non-peptidic,  
 non-peptidomimetic, organic molecules that act as modulators of  
 mammalian complement C5a receptors, preferably ones that act as high  
 affinity C5a receptor ligands and also to such ligands that act as  
 antagonists or inverse agonists of complement C5a receptors. Preferred  
 compounds of the invention possess some or all of the following  
 properties in that they are: 1) multi-aryl in structure, 2) heteroaryl  
 in structure, 3) a pharmaceutically acceptable oral dose can provide a  
 detectable in vitro effect, 4) comprise fewer than four or preferably no  
 amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at  
 nanomolar or sub-nanomolar concentrations. This invention also relates  
 to pharmaceutical compositions comprising such compounds and the use of  
 such compounds in treating a variety of inflammatory and immune system  
 disorders. Additionally, this invention relates to the use of such  
 compounds as probes for the localization of C5a receptors.  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 439558-41-5P  
 (preparation of substituted imidazoles, pyrazoles and amides as high  
 affinity C5a receptor modulators)  
 RN 439558-41-5 USPATFULL  
 CN Isoquinoline, 2-([1-(1-butyl-2-phenyl-1H-imidazol-5-yl)methyl]-1-cyclopentyl-  
 1,2,3,4-tetrahydro- (CA INDEX NAME)




L20 ANSWER 1 OF 14 USPATFULL on STN (Continued)  
 AN 2005:101469 USPATFULL  
 TI High affinity small molecule C5a receptor modulators  
 IN Thurkauf, Andrew, Danbury, CT, UNITED STATES  
 He, Xiao-shu, Branford, CT, UNITED STATES  
 Zhao, He, Branford, CT, UNITED STATES  
 Peterson, John, Madison, CT, UNITED STATES  
 Zhang, Xiaoyan, Bridgewater, NJ, UNITED STATES  
 Brodbeck, Robbin, Madison, CT, UNITED STATES  
 Krause, James, Madison, CT, UNITED STATES  
 Maynard, George, Clinton, CT, UNITED STATES  
 Hutchison, Alan, Madison, CT, UNITED STATES  
 PA Neurogen Corporation, Branford, CT, UNITED STATES (U.S. corporation)  
 PI US-----6884815 B1 20050426  
 AI 2003US-000461311 20030612 (10)  
 RLI Division of Ser. No. 2000US-000672071, filed on 28 Sep 2000, Pat. No.  
 US-----6723743  
 PRAI 2000US-000224036P 20000809 (60)  
 2000US-000221787P 20000731 (60)  
 2000US-000212449P 20000616 (60)  
 2000US-000202749P 20000508 (60)  
 1999US-000156390P 19990928 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Seaman, D. Margaret  
 LREP Corless, Peter F., Alexander, John B., Edwards & Angell, LLP  
 CLMN Number of Claims: 48  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
 LN.CNT 12183  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention relates to low molecular weight, non-peptidic,  
 non-peptidomimetic, organic molecules that act as modulators of  
 mammalian complement C5a receptors, preferably ones that act as high  
 affinity C5a receptor ligands and also to such ligands that act as  
 antagonists or inverse agonists of complement C5a receptors. Preferred  
 compounds of the invention possess some or all of the following  
 properties in that they are: 1) multi-aryl in structure, 2) heteroaryl  
 in structure, 3) a pharmaceutically acceptable oral dose can provide a  
 detectable in vitro effect, 4) comprise fewer than four or preferably no  
 amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at  
 nanomolar or sub-nanomolar concentrations.  
 This invention also relates to pharmaceutical compositions comprising  
 such compounds and the use of such compounds in treating a variety of  
 inflammatory and immune system disorders. Additionally, this invention  
 relates to the use of such compounds as probes for the localization of C5a  
 receptors.  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 439558-41-5P  
 (preparation of substituted imidazoles, pyrazoles and amides as high  
 affinity C5a receptor modulators)  
 RN 439558-41-5 USPATFULL  
 CN Isoquinoline, 2-([1-(1-butyl-2-phenyl-1H-imidazol-5-yl)methyl]-1-cyclopentyl-  
 1,2,3,4-tetrahydro- (CA INDEX NAME)



AN ANSWER 4 OF 14 USPATFUEL ON STN  
 AN 2005:17403 USPATFUEL  
 II Phenyl substituted 5-membered nitrogen containing heterocycles for the  
 treatment of obesity  
 IN Zhang, Chenzhi, Mulberry Lane, CA, UNITED STATES  
 Colish, Philip D.G., New Haven, CT, UNITED STATES  
 O'Connor, Stephen J., Guilford, CT, UNITED STATES  
 Wickens, Philip, Wallingford, CT, UNITED STATES  
 Zhang, Hai-Jun, Middletown, CT, UNITED STATES  
 PI AU-20050014805 AU 20050123  
 AI AU 200405-000490826 AU 20040326 (10)  
 200200-00032895 20020103  
 PRAI 20010105-000329236P 20011012 (60)  
 DT Utility  
 FS APPLICATION  
 LRP JEFFREY M. GREENMAN, BAYER PHARMACEUTICALS CORPORATION, 400 MORGAN LANE,  
 WEST HAVEN, CT, 06516  
 CLMN Number of Claims: 80  
 ECL Exemplary Claim: 1  
 DWN No Drawings  
 LN CNT 4902  
 CA INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention relates to novel heterocyclic compounds, compositions,  
 and methods for treating or preventing obesity and obesity-related  
 diseases. \*\*STRT\*\*#

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
IT 521084-04-8P  
(preparation of arylazolecaboxamides for the treatment of obesity)  
RN 521084-04-8 USPAT(FULL)  
CN Propanoic acid, 2-[[4-[(1-(2-methoxyethyl)-4-methyl-5-(1-piperidinylcarbonyl)-1H-imidazol-2-yl)phenyl]thio]-2-methyl- (CA INDEX NAME)




```

AN 20 ANSWER 5 OF 14 USPATFULL ON 57N
AI 2004:261944 USPATFULL
TI Substituted tetrahydroarisoquinolines as C5a receptor modulators
IN Lee, Kyungae, Gulliford, CT, UNITED STATES
MIL Mitchell, Scott A., East Haven, CT, UNITED STATES
OHLINGER, Robert, Madison, CT, UNITED STATES
Zhang, Lufan, Branford, CT, UNITED STATES
Zhao, He, Branford, CT, UNITED STATES
Curtis, Kevin S., North Branford, CT, UNITED STATES
DI US-2004/020446 AI 20040415 (10)
US-----619368Z B2 20050712
2004/05-00084262 AI 20040415 (10)
PLI Continuation of Ser. US-2003/0050401-13, filed on 27 Mar 2003,
GRANTED, Pat. No. US-----6777422
PRAI 2002/05-000368199P 20020328 (60)
DT Utility
DI APPLICATION
LREP Ann T. Kadecek, Neurogen Corporation, 35 NE Industrial Rd., Branford,
CT, 06415
CIRM Number of Claims: 22
ECL Exemplary Claim: C1M-01-30
DMMR No Drawings
LN.CNT 3114
CSA INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted tetrahydroarisoquinolines and related compounds are provided.
Such compounds are ligands that may be used to modulate C5a receptor
activity in vivo or in vitro, and are particularly useful in the
treatment of conditions associated with pathological C5a receptor
activation in humans, domesticated companion animals and livestock
animals. Pharmaceutical compositions and methods for using them to treat
neurological disorders are also provided, as are methods for using such ligands for
receptor localization studies. #A5TR#11

```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
IT 610289-03-7P  
(preparation of new aryl imidazoles and related compds. as C5a receptor modulators)  
RN 610289-03-7 USPDATAFULL  
CN Isoquinoline, 2-[(1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)




|      |                                                                  |                  |
|------|------------------------------------------------------------------|------------------|
| LN   | ANSWER 6 OF 14                                                   | USPATFULL ON STN |
| AN   | 2004:152202                                                      | USPATFULL        |
| TI   | Aryl imidazoles and related compounds as C5a receptor modulators |                  |
| IN   | Lutke, George P., Clinton, CT, UNITED STATES                     |                  |
|      | Maynard, George D., Clinton, CT, UNITED STATES                   |                  |
|      | Mitchell, Scott, East Haven, CT, UNITED STATES                   |                  |
|      | Turkhauf, Andrew, Danbury, CT, UNITED STATES                     |                  |
|      | Xie, Langdong, Guilford, CT, UNITED STATES                       |                  |
|      | Zhang, Luhan, Branford, CT, UNITED STATES                        |                  |
|      | Zhang, Suoming, Branford, CT, UNITED STATES                      |                  |
|      | Zhao, He, Branford, CT, UNITED STATES                            |                  |
|      | Chenard, Bertrand L., Waterford, CT, UNITED STATES               |                  |
|      | Gao, Yang, Branford, CT, UNITED STATES                           |                  |
|      | Han, Bingcong, Hamden, CT, UNITED STATES                         |                  |
| PA   | He, Xiao Shu, Branford, CT, UNITED STATES                        |                  |
| PI   | Neurogen Corporation (U.S. corporation)                          |                  |
| AI   | US-20040116424                                                   | AI 200401617     |
| US   | US-2005-1186734                                                  | US-2005-03096    |
| PI   | US-20040045989                                                   | AI 20040328 (10) |
| PRAI | 200205-000369112P                                                | 20020329 (60)    |
|      | 200205-000392145P                                                | 20020266 (60)    |
| DT   | Utility                                                          |                  |
| FS   | APPLICATION                                                      |                  |
| LREP | EDWARDS & ANGELL, LLP, P.O. BOX 9169, BOSTON, MA, 02209          |                  |
| CLNN | Number of Claims: 87                                             |                  |
| EXT  | Exemplary Claim: 1                                               |                  |
| DRWN | No Drawings                                                      |                  |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides Aryl substituted imidazoles, pyrazoles, pyridines and related compounds of the Formula \*\$STR1## where the ring system represented by \*\$STR2## is a 5 membered heterocyclic ring system, in which x is 0, A is chosen from carbon and heteroatoms nitrogen, oxygen, and sulfur, and E and G are independently carbon or nitrogen, provided that the 5 membered heterocyclic ring system does not contain more than 3 heteroatoms or more than 2 oxygen or sulfur atoms, the 6 membered heterocyclic ring system in which x is 1, A, B, E, and G are independently chosen from carbon and nitrogen, provided that the 6 membered heterocyclic ring system does not contain more than 3 nitrogen atoms. The remaining variables, Ar.sub.1, Ar.sub.2, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, y and z are defined herein

Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
IT 610289-03-7P  
(preparation of new aryl imidazoles and related compds. as C5a receptor modulators)  
RN 610289-03-7 USPATFULL  
CN Isoquinoline, 2-[(1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)



L20 ANSWER 6 OF 14 USPATFULL on STN (Continued)

04/03/2008 Page 45

L20 ANSWER 7 OF 14 USPATFULL on STN  
 AN 2004:97394 USPATFULL  
 TI High affinity small molecule C5a receptor modulators  
 IN Thurkauf, Andrew, Danbury, CT, United States  
 He, Xiao-shu, Branford, CT, United States  
 Shao, He, Branford, CT, United States  
 Peterson, John, Madison, CT, United States  
 Zhang, Xiaoyan, Bridgewater, NJ, United States  
 Brodebeck, Robin, Madison, CT, United States  
 Krause, James, Madison, CT, United States  
 Maynard, George, Clinton, CT, United States  
 Hutchison, Alan, Madison, CT, United States  
 PA Neurogen Corporation, Branford, CT, United States (U.S. corporation)  
 PI US-----6723743 B1 20040420  
 AI 2000US-000672071 20000928 (9)  
 PRAI 2000US-000224036P 20000809 (60)  
 2000US-000221787P 20000731 (60)  
 2000US-00012499P 20000616 (60)  
 2000US-00002749P 20000508 (60)  
 1999US-000156390P 19990928 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Seaman, D. Margaret  
 LREP Horvath, Leslie Anne, Fidel, Seth, Edwards & Angell, LLP  
 CLMN Number of Claims: 44  
 ECL Exemplary Claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT #202


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors, preferably human C5a receptors. Preferred compounds of the invention possess one or more, and preferably two or more, three or more, four or more, or all of the following properties in that they are: 1) multi-aryl in structure (having a plurality of un-fused or fused aryl groups), 2) heteroaryl in structure, 3) orally available in vivo (such that a sub-lethal or preferably a pharmaceutically acceptable oral dose can provide a detectable in vitro effect such as a reduction of C5a-induced neutropenia), 4) comprised of fewer than four, preferably fewer than three, or fewer than two, or no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar concentrations and preferably at sub-nanomolar concentrations. Specifically exemplified representative compounds include, but are not limited to optionally substituted arylimidazoles, optionally substituted arylpyridis, optionally substituted aryl-substituted cycloalkylimidazoles, optionally substituted arylpyrazoles, optionally substituted benzimidazoles, optionally substituted aryl-substituted tetrahydroisoquinolines, and optionally substituted biaryl carboxamides. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 439558-41-5P  
 (preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators)  
 RN 439558-41-5 USPATFULL  
 CN Isoquinoline, 2-[(1-butyl-2-phenyl-1H-imidazol-5-yl)methyl]-1-cyclopentyl-1,2,3,4-tetrahydro- (CA INDEX NAME)

L20 ANSWER 7 OF 14 USPATFULL on STN (Continued)




L20 ANSWER 8 OF 14 USPATFULL on STN  
 AN 2004:7829 USPATFULL  
 TI Substituted tetrahydroisoquinolines as C5a receptor modulators  
 IN Lee, Kyungae, Guilford, CT, UNITED STATES  
 Mitchell, Scott, East Haven, CT, UNITED STATES  
 Ohliger, Robert, Madison, CT, UNITED STATES  
 Zhang, Lu Yan, Branford, CT, UNITED STATES  
 Shao, He, Branford, CT, UNITED STATES  
 Currie, Kevin, North Branford, CT, UNITED STATES  
 PI US-20040006969 A1 20040108  
 US-----6777422 B2 20040817  
 AI 2003US-000401135 A1 20030327 (10)  
 PRAI 2002US-000368199P 20020328 (60)  
 DT Utility  
 FS APPLICATION  
 LREP Leslie-Anne Horvath, Patent Department, Neurogen Corporation, 35 NE Industrial Road, Branford, CT, 06405  
 CLMN Number of Claims: 52  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 3786

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ##STR1##  
 Substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 610289-03-7P  
 (preparation of new aryl imidazoles and related compds. as C5a receptor modulators)  
 RN 610289-03-7 USPATFULL  
 CN Isoquinoline, 2-[(1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)




L20 ANSWER 9 OF 14 USPATFULL on STN  
 AN 2003:100165 USPATFULL  
 TI Amino piperidine derivatives  
 IN Edlin, Christopher David, Balderton, UNITED KINGDOM  
 Redshaw, Sally, Shillington, UNITED KINGDOM  
 Smith, Ian Edward David, Willington, UNITED KINGDOM  
 PRAI Walter, Darryl Simon, Knebworth, UNITED KINGDOM  
 PI US-20030069276 A1 20030410  
 AI 2002US-000104117 A1 20020322 (10)  
 PRAI 2001GB-00008099 20010330  
 DT Utility  
 FS APPLICATION  
 LREP HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUILEX, NJ, 07110  
 CLMN Number of Claims: 13  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 4435

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention comprises novel aminopiperidine derivatives, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds of formula I prevent the human immunodeficiency virus (HIV) from entering cells by blocking interaction of the viral envelope protein gp120 with a chemokine receptor on the cell surface. The compounds of this invention may be advantageously used as therapeutic agents for the treatment of diseases mediated by the human immunodeficiency virus (HIV), either alone or in combination with other inhibitors of HIV viral replication or with pharmacoenhancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 466663-31-0P, 1-Benzyl-1-[1-[(3-benzyl-5-methyl-2-[4-(trifluoromethyl)phenyl]-3H-imidazol-4-yl)methyl]-4-piperidinyl]-3-methylurea  
 (HIV inhibitor; preparation of imidazolylalkyl-aminopiperidines as HIV inhibitors)  
 RN 466663-31-0 USPATFULL  
 CN Urea, N'-methyl-N-[1-[[4-methyl-1-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-3H-imidazol-5-yl)methyl]-4-piperidinyl]-N-(phenylmethyl)- (CA INDEX NAME)



L20 ANSWER 10 OF 14 USPTAT2 on STN  
 AN 2003:24182 USPTAT2  
 TI Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands  
 IN Thurkauf, Andrew, Danbury, CT, UNITED STATES  
 Norvath, Raymond F., Guilford, CT, UNITED STATES  
 Yuan, Jun, Guilford, CT, UNITED STATES  
 Peterson, John M., Madison, CT, UNITED STATES  
 PA Neurogen Corporation, Corporation of the State of Delaware, Branford, CT (U.S. corporation)  
 PI US-2003018025 A1 20030123  
 AI 2002US-000156262 A1 20020528 (10)  
 RLI Continuation of Ser. No. 1999US-000281169, filed on 30 Mar 1999, PENDING  
 Continuation of Ser. No. 1995US-000476291, filed on 7 Jun 1995, ABANDONED  
 DT Utility  
 FS APPLICATION  
 LREP Steven J. Sarussi, McDonnell Boehnen Hulbert & Berghoff, 32nd Floor, 300 S. Wacker Drive, Chicago, IL, 60606  
 CLMN Number of Claims: 26  
 ECL Exemplary Claim: 1  
 DRWN 3 Drawing Page(s)  
 LN.CNT 2298  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Disclosed are compounds of the formula: ##STR1##


wherein R.sub.1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R.sub.3 and R.sub.4 are organic or inorganic substituents which may together form ring structures; m is zero, one or two; and R.sub.5 and R.sub.6 are organic or inorganic substituents;

and the pharmaceutically acceptable addition salts thereof,

which compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 179332-44-6P  
 (preparation of imidazole derivs. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)  
 RN 179332-44-6 USPTAT2  
 CN Piperidine, 1-[(1-methyl-2-phenyl-1H-imidazol-5-yl)methyl]-4-(phenylmethyl)- (CA INDEX NAME)




L20 ANSWER 11 OF 14 USPTAT2 on STN  
 AN 2007:30883 USPTAT2  
 TI High affinity small molecule C5a receptor modulators  
 IN Thurkauf, Andrew, Danbury, CT, UNITED STATES  
 He, Xiao-shu, Branford, CT, UNITED STATES  
 Zhao, He, Branford, CT, UNITED STATES  
 PA Neurogen Corporation, Branford, CT, UNITED STATES (U.S. corporation)  
 PI US-6884815 B2 20070918  
 AI 2004US-000453731 20040524 (10)  
 RLI Division of Ser. No. 2003US-000461311, filed on 12 Jun 2003, Pat. No. US-6884815 Division of Ser. No. 2000US-000672071, filed on 28 Sep 2000, Pat. No. US-6723743  
 PRAI 1999US-000156390P 19990928 (60)  
 2000US-000202749P 20000508 (60)  
 2000US-000212449P 20000616 (60)  
 2000US-000221782P 20000731 (60)  
 2000US-000224036P 20000809 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Seaman, D. Margaret  
 LREP Edwards Angell Palmer & Dodge LLP, Corless, Peter F., Kim, Dwight D.  
 CLMN Number of Claims: 18  
 ECL Exemplary claim: 1  
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
 LN.CNT 10713  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations.

This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 439558-41-5P  
 (preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators)  
 RN 439558-41-5 USPTAT2  
 CN Isoquinoline, 2-[(1-butyl-2-phenyl-1H-imidazol-5-yl)methyl]-1-cyclopentyl-1,2,3,4-tetrahydro- (CA INDEX NAME)




L20 ANSWER 12 OF 14 USPTAT2 on STN  
 AN 2004:261944 USPTAT2  
 TI Substituted tetrahydroisoquinolines as C5a receptor modulators  
 IN Lee, Kyungae, Guilford, CT, UNITED STATES  
 Mitchell, Scott A., East Haven, CT, UNITED STATES  
 Ohliger, Robert, Madison, CT, UNITED STATES  
 Zhang, LuYan, Branford, CT, UNITED STATES  
 Zhao, He, Branford, CT, UNITED STATES  
 Currie, Kevin S., North Branford, CT, UNITED STATES  
 PA Neurogen Corporation, Branford, CT, UNITED STATES (U.S. corporation)  
 PI US-6916830 B2 20050712  
 AI 2004US-000824826 20040415 (10)  
 RLI Continuation of Ser. No. 2003US-000401135, filed on 27 Mar 2003, Pat. No. US-6770422  
 PRAI 2002US-000368199P 20020328 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Davis, Zinna Northington  
 LREP Kadlecsek, Ann T., Fidel, Seth A.  
 CLMN Number of Claims: 13  
 ECL Exemplary claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT 3032  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 610289-03-7P  
 (preparation of new aryl imidazoles and related compds. as C5a receptor modulators)  
 RN 610289-03-7 USPTAT2  
 CN Isoquinoline, 2-[(1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)




L20 ANSWER 13 OF 14 USPTAT2 on STN  
 AN 2004:152202 USPTAT2  
 TI Aryl imidazoles and related compounds as C5a receptor modulators  
 IN Maynard, George D., Clinton, CT, UNITED STATES  
 Thurkauf, Andrew, Danbury, CT, UNITED STATES  
 Zhao, He, Branford, CT, UNITED STATES  
 Chenard, Bertrand L., Waterford, CT, UNITED STATES  
 Gao, Yang, Branford, CT, UNITED STATES  
 PA Neurogen Corporation, Branford, CT, UNITED STATES (U.S. corporation)  
 PI US-67186734 B2 20070306  
 AI 2003US-000405989 20030328 (10)  
 PRAI 2002US-000392145P 20020626 (60)  
 2002US-000369112P 20020329 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Saeed, Kamal A.; Assistant Examiner: Anderson, Rebecca  
 LREP Edwards Angell Palmer & Dodge LLP, Corless, Peter F., Alexander, John B.  
 CLMN Number of Claims: 36  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 9069  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention provides Aryl substituted imidazoles, pyrazoles, pyridines and related compounds of the Formula ##STR1## where the variables are defined herein.


Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 610289-03-7P  
 (preparation of new aryl imidazoles and related compds. as C5a receptor modulators)  
 RN 610289-03-7 USPTAT2  
 CN Isoquinoline, 2-[(1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)



L20 ANSWER 14 OF 14 USPAT2 on STN  
 AN 20047829 USPAT2  
 TI Substituted tetrahydroisoquinolines as C5a receptor modulators  
 IN Lee, Kyungae, Guilford, CT, United States  
 Mitchell, Scott, East Haven, CT, United States  
 Ohliger, Robert, Madison, CT, United States  
 Zhang, Lu Yan, Branford, CT, United States  
 Zhao, He, Branford, CT, United States  
 Currie, Kevin, North Branford, CT, United States  
 PA Neurogen Corp., Branford, CT, United States (U.S. corporation)  
 PI US-----6777422 B2 20040817  
 AI 2003US-000401135 20030337 (10)  
 PRAI 2002US-000368199P 20020328 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Davis, Zinna Northington  
 LREP Kaklecek, Ann T., Fidel, Seth A.  
 CLMN Number of Claims: 20  
 ECL Exemplary Claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT 3353  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Substituted tetrahydroisoquinolines and related compounds are provided.  
 Such compounds are ligands that may be used to modulate C5a receptor  
 activity in vivo or in vitro, and are particularly useful in the  
 treatment of conditions associated with pathological C5a receptor  
 activation in humans, domesticated companion animals and livestock  
 animals. Pharmaceutical compositions and methods for using them to treat  
 such disorders are provided, as are methods for using such ligands for  
 receptor localisation studies. ##GRI##  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 610289-03-7P  
 (preparation of new aryl imidazoles and related compds. as C5a receptor  
 modulators)  
 RN 610289-03-7 USPAT2  
 CN Isoquinoline, 2-[[1-(2,3-dihydro-1H-inden-2-yl)-2-phenyl-1H-imidazol-5-  
 yl)methyl]-1,2,3,4-tetrahydro-1-(2-methylphenyl)- (CA INDEX NAME)



=> d bib abs hitrn fhitstr l22 tot

L22 ANSWER 1 OF 2 USPATFULL on STN  
 AN 2007155335 USPATFULL  
 TI HEAT FIXING ROLL AND FIXING BELT  
 IN HIRABAYASHI, Satao, Annaka-shi, JAPAN  
 IINO, Miki, Annaka-shi, JAPAN  
 Tomizawa, Nobumasa, Annaka-shi, JAPAN  
 Meguriya, Noriyuki, Annaka-shi, JAPAN  
 PA SHI-ETSU CHEMICAL CO., LTD., Chiyoda-ku, JAPAN (non-U.S. corporation)  
 PI US-20070135555 A1 20070614  
 AI 2006US-000563401 A1 20061127 (11)  
 PRAI 2005JP-000341571 20051128  
 DT Utility  
 FS APPLICATION  
 LREP OBLON, SPIVAK, MCCLELLAND, MAIR & NEUSTADT, P.C., 1940 DUKE STREET,  
 ALEXANDRIA, VA, 22314, US  
 CLMN Number of Claims: 12  
 ECL Exemplary Claim: 1  
 DRWN No Drawings

LN CNT 751  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A heat fixing roll or belt having a silicone rubber layer which is formed by curing a silicone rubber composition comprising (A) 100 pbw of an organopolysiloxane having at least two silicon-bonded alkanyl radicals in a molecule, (B) 20-500 pbw of a metallic silicon powder having an average particle size of up to 100  $\mu$ m, and (C) an effective amount of a curing agent. The silicone rubber layer has a high heat conductivity and long-term temperature durability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 832153-16-9P 832153-17-0P 832153-18-1P

832153-19-2P 832153-20-5P 832153-21-6P  
 832153-22-7P 832153-23-8P 832153-24-9P  
 832153-25-0P 832153-26-1P 832153-27-2P  
 832153-28-3P 832153-29-4P 832153-30-7P  
 832153-31-8P 832153-32-9P 832153-33-0P  
 832153-34-1P 832153-35-2P 832153-36-3P  
 832153-37-4P 832153-38-5P 832153-39-6P  
 832153-40-9P 832153-41-0P 832153-42-1P  
 832153-43-2P 832153-44-3P 832153-45-4P  
 832153-46-5P 832153-47-6P 832153-48-7P  
 832153-49-8P 832153-50-1P 832153-51-2P  
 832153-52-3P 832153-53-4P 832153-54-5P  
 832153-55-6P 832153-56-7P 832153-57-8P  
 832153-58-9P 832153-59-0P 832153-60-3P  
 832153-61-4P 832153-62-5P 832153-63-6P  
 832153-64-7P 832153-65-8P 832153-66-9P  
 832153-67-0P 832153-68-1P 832153-69-2P  
 832153-70-5P 832153-71-6P 832153-72-7P  
 832153-73-8P 832153-74-9P 832153-75-0P  
 832153-76-1P 832153-77-2P 832153-78-3P  
 832153-79-4P 832153-80-7P 832153-81-8P  
 832153-82-9P 832153-83-0P 832153-84-1P  
 832153-85-2P 832153-86-3P 832153-87-4P  
 832153-88-5P 832153-89-6P 832153-90-9P  
 832153-91-0P 832153-92-1P 832153-93-2P  
 832153-94-3P 832153-95-4P 832153-96-5P  
 832153-97-6P 832153-98-7P 832153-99-8P  
 832154-00-4P 832154-01-5P 832154-02-6P  
 832154-03-7P 832154-04-8P 832154-05-9P  
 832154-06-0P 832154-07-1P 832154-08-2P  
 832154-09-3P 832154-10-6P 832154-11-7P  
 832154-12-8P 832154-13-9P 832154-14-0P  
 832154-15-1P 832154-16-4P 832154-17-5P  
 832154-18-6P 832154-19-7P 832154-20-8P  
 832154-21-9P 832154-22-0P 832154-23-1P  
 832154-24-2P 832154-25-3P 832154-26-4P  
 832154-27-5P 832154-28-6P 832154-29-7P  
 832154-30-8P 832154-31-9P 832154-32-0P  
 832154-33-1P 832154-34-2P 832154-35-3P  
 832154-36-4P 832154-37-5P 832154-38-6P  
 832154-39-7P 832154-40-8P 832154-41-9P  
 832154-42-0P 832154-43-1P 832154-44-2P  
 832154-45-3P 832154-46-4P 832154-47-5P  
 832154-48-6P 832154-49-7P 832154-50-8P  
 832154-51-9P 832154-52-0P 832154-53-1P  
 832154-54-2P 832154-55-3P 832154-56-4P  
 832154-57-5P 832154-58-6P 832154-59-7P  
 832154-60-8P 832154-61-9P 832154-62-0P  
 832154-63-1P

L22 ANSWER 2 OF 2 USPATFULL on STN

AN 2006182513 USPATFULL  
 TI Substituted (heterocycloalkyl)methylazole derivatives as c5a receptor modulators  
 IN Zhang, Suoming, Madison, CT, UNITED STATES  
 Zhao, He, Madison, CT, UNITED STATES  
 Gao, Yang, Madison, CT, UNITED STATES  
 Thurkauf, Andrew, Ridgefield, CT, UNITED STATES  
 Maynard, George D, Clinton, CT, UNITED STATES  
 Chmward, Bertand L, Waterford, CT, UNITED STATES  
 Ohliger, Robert, Deep River, CT, UNITED STATES  
 Peterson, John M, Durham, CT, UNITED STATES  
 PA Neurogen Corporation, Branford, CT, UNITED STATES, 06405 (U.S. corporation)  
 PI US-20060154917 A1 20060713 <--  
 2004US-000563401 A1 20040630 (10)  
 2006WO-US0921191 20040630  
 PRAI 2003US-000484684P 20030703 (60)  
 DT Utility  
 FS APPLICATION  
 LREP EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205, US  
 CLMN Number of Claims: 47  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN CNT 3926

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heterocycloalkyl)methylazole derivatives of Formula (I) are provided: Formula I wherein A is oxygen, sulfur, or NR; J and K and each L are independently oxygen, sulfur, NH, or CH.sub.2 and the remaining variables are defined herein. Such compounds are modulators of c5a receptors, and preferably bind to c5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at c5a receptors. Also provided herein are pharmaceutical compositions comprising such compounds, as well as methods for using such compounds in treating a variety of inflammatory and immune system disorders. ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 832153-16-9P 832153-17-0P 832153-18-1P

832153-19-2P 832153-20-5P 832153-21-6P  
 832153-22-7P 832153-23-8P 832153-24-9P  
 832153-25-0P 832153-26-1P 832153-27-2P  
 832153-28-3P 832153-29-4P 832153-30-7P  
 832153-31-8P 832153-32-9P 832153-33-0P  
 832153-34-1P 832153-35-2P 832153-36-3P  
 832153-37-4P 832153-38-5P 832153-39-6P  
 832153-40-9P 832153-41-0P 832153-42-1P  
 832153-43-2P 832153-44-3P 832153-45-4P  
 832153-46-5P 832153-47-6P 832153-48-7P  
 832153-49-8P 832153-50-1P 832153-51-2P  
 832153-52-3P 832153-53-4P 832153-54-5P  
 832153-55-6P 832153-56-7P 832153-57-8P  
 832153-58-9P 832153-59-0P 832153-60-3P  
 832153-61-4P 832153-62-5P 832153-63-6P  
 832153-64-7P 832153-65-8P 832153-66-9P  
 832153-67-0P 832153-68-1P 832153-69-2P  
 832153-70-5P 832153-71-6P 832153-72-7P  
 832153-73-8P 832153-74-9P 832153-75-0P  
 832153-76-1P 832153-77-2P 832153-78-3P  
 832153-79-4P 832153-80-7P 832153-81-8P  
 832153-82-9P 832153-83-0P 832153-84-1P  
 832153-85-2P 832153-86-3P 832153-87-4P  
 832153-88-5P 832153-89-6P 832153-90-9P  
 832153-91-0P 832153-92-1P 832153-93-2P  
 832153-94-3P 832153-95-4P 832153-96-5P  
 832153-97-6P 832153-98-7P 832153-99-8P  
 832154-00-4P 832154-01-5P 832154-02-6P  
 832154-03-7P 832154-04-8P 832154-05-9P  
 832154-06-0P 832154-07-1P 832154-08-2P  
 832154-09-3P 832154-10-6P 832154-11-7P  
 832154-12-8P 832154-13-9P 832154-14-0P  
 832154-15-1P 832154-16-4P 832154-17-5P  
 832154-18-6P 832154-19-7P 832154-20-8P  
 832154-21-9P 832154-22-0P 832154-23-1P  
 832154-24-2P 832154-25-3P 832154-26-4P  
 832154-27-5P 832154-28-6P 832154-29-7P  
 832154-30-8P 832154-31-9P 832154-32-0P  
 832154-33-1P 832154-34-2P 832154-35-3P  
 832154-36-4P 832154-37-5P 832154-38-6P  
 832154-39-7P 832154-40-8P 832154-41-9P  
 832154-42-0P 832154-43-1P 832154-44-2P  
 832154-45-3P 832154-46-4P 832154-47-5P


L22 ANSWER 1 OF 2 USPATFULL on STN (Continued)

832154-44-0P 832154-45-1P 832154-46-2P  
 832154-47-3P 832154-48-4P 832154-49-5P  
 832154-50-6P 832154-51-7P 832154-52-8P  
 832154-53-9P 832154-54-0P 832154-55-1P  
 832154-56-2P 832154-57-3P 832154-58-4P  
 832154-59-5P 832154-60-6P 832154-61-7P  
 832154-62-8P 832154-63-9P 832154-64-0P  
 832154-65-1P 832154-66-2P 832154-67-3P  
 832154-68-4P 832154-69-5P 832154-70-6P  
 832154-71-7P 832154-72-8P 832154-73-9P  
 832154-74-0P 832154-75-1P 832154-76-2P  
 832154-77-3P 832154-78-4P 832154-79-5P  
 832154-80-6P 832154-81-7P 832154-82-8P  
 832154-83-9P 832154-84-0P 832154-85-1P  
 832154-86-2P 832154-87-3P 832154-88-4P  
 832154-89-5P 832154-90-6P 832154-91-7P  
 832154-92-8P 832154-93-9P 832154-94-0P  
 832154-95-1P  
 (prepn. of heterocycloalkylmethylimidazoles and related comps. as c5a receptor modulators for the treatment of inflammatory disorders)  
 IT 832153-05-2P 832153-06-3P 832153-07-4P  
 (preparation of heterocycloalkylmethylimidazoles and related comps. as c5a receptor modulators for the treatment of inflammatory disorders)  
 IT 832153-16-9P  
 (preparation of heterocycloalkylmethylimidazoles and related comps. as c5a receptor modulators for the treatment of inflammatory disorders)  
 RN 832153-16-9 USPATFULL  
 CN Piperidine, 1-[[1-butyl-4-chloro-2-(2,6-diethylphenyl)-1H-imidazol-5-yl]methyl]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



L22 ANSWER 2 OF 2 USPATFULL on STN (Continued)

832154-48-0P 832154-50-4P 832154-51-5P  
 832154-52-6P 832154-53-7P 832154-54-8P  
 832154-55-9P 832154-56-0P 832154-57-1P  
 832154-58-2P 832154-59-3P 832154-60-4P  
 832154-61-7P 832154-62-8P 832154-63-9P  
 832154-64-0P 832154-65-1P 832154-66-2P  
 832154-67-3P 832154-68-4P 832154-69-5P  
 832154-70-6P 832154-71-7P 832154-72-8P  
 832154-73-9P 832154-74-0P 832154-75-1P  
 832154-76-2P 832154-77-3P 832154-78-4P  
 832154-79-5P 832154-80-6P 832154-81-7P  
 832154-82-8P 832154-83-9P 832154-84-0P  
 832154-85-1P 832154-86-2P 832154-87-3P  
 832154-88-4P 832154-89-5P 832154-90-6P  
 832154-91-7P 832154-92-8P 832154-93-9P  
 832154-94-0P 832154-95-1P  
 (prepn. of heterocycloalkylmethylimidazoles and related comps. as c5a receptor modulators for the treatment of inflammatory disorders)  
 IT 832153-05-2P 832153-06-3P 832153-07-4P  
 (preparation of heterocycloalkylmethylimidazoles and related comps. as c5a receptor modulators for the treatment of inflammatory disorders)  
 IT 832153-16-9P  
 (preparation of heterocycloalkylmethylimidazoles and related comps. as c5a receptor modulators for the treatment of inflammatory disorders)  
 RN 832153-16-9 USPATFULL  
 CN Piperidine, 1-[[1-butyl-4-chloro-2-(2,6-diethylphenyl)-1H-imidazol-5-yl]methyl]-2-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



=&gt; d his

(FILE 'HOME' ENTERED AT 09:45:28 ON 04 MAR 2008)

FILE 'HCAPLUS' ENTERED AT 09:46:19 ON 04 MAR 2008

L1 1 US20060154917/PN

FILE 'REGISTRY' ENTERED AT 09:46:50 ON 04 MAR 2008

FILE 'HCAPLUS' ENTERED AT 09:46:52 ON 04 MAR 2008

L2 TRA L1 1- RN : 227 TERMS

FILE 'REGISTRY' ENTERED AT 09:46:53 ON 04 MAR 2008

L3 227 SEA L2  
ACT J401C1GXIII/A

L4 STR

L5 ( 908950)SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES

L6 739 SEA FILE=REGISTRY SUB=L5 SSS FUL L4

L7 STR L4

L8 10 L7 SAM SUB=L6

L9 175 L7 FULL SUB=L6

SAV TEM J401C1S1/A L9

L10 161 L9 AND L3

L11 14 L9 NOT L10

FILE 'HCAPLUS' ENTERED AT 09:51:17 ON 04 MAR 2008

L12 1 L10

L13 11 L11

L14 9 L13 AND (PD&lt;=20030703 OR AD&lt;=20030703 OR AD&lt;=20030703)

L15 2 L13 NOT L14

FILE 'HCAOLD' ENTERED AT 09:54:07 ON 04 MAR 2008

L16 0 L9

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 09:54:26 ON 04 MAR 2008

L17 16 L9

L18 1 L17 AND L1

L19 15 L17 NOT L18

L20 14 L19 AND L11

L21 1 L19 AND L10

L22 2 L18,L21

=&gt;